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Academicians dedicate a significant part of their career to conducting research 
and publishing their findings. A major milestone in an academician’s career involves 
being successfully funded to conduct research work.  One measure of success in 
conducting medical research is the ability to obtain federal funding through the U.S. 
Department of Health and Human Services, National Institutes of Health (NIH) and its 
related Institutes, by submitting an extensive and competitive application for the agency’s 
scientific review. The application process is arduous and requires the development of 
scientific and administrative components for submission within tight timelines, and it can 
take more than one attempt to submit a successful proposal resulting in funding. The 
submission process for each application can take up to eight months of preparation as its 
development requires dedication, patience, and passion. Researchers, who attempt the 
federal funding application process, speak to the need for their predecessors to provide 
support and directions systematically, to help them understand the funding opportunity 
announcement, application requirements, and plan for success. 
This project involves the construction of a manual to assist researchers with 
submitting an NHLBI grant application using the funding opportunity announcement 
PAR-18-407 for multi-site clinical trials. The manual provides a step by step approach to 
completing the application sections using this FOA, the SF424 form and the author’s own 
experience in submitting a grant to this announcement over three years. Instructions for 
each section of the application including sample templates are included in the manual to 
guide the PI with the successful planning and development of a robust application, 
effective use of time and establishing collaborations. The manual will help complete an 
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entire PAR-18-407 application successfully to obtain a favorable review outcome which 
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Funding Opportunity Announcement (FOA): Advertisements announcing the 
availability of funds to support research, released by funding agencies such as the NIH  
 
Grantsmanship: The skill of applying for grants and obtaining funding successfully. 
 
Program Announcement special receipt/referral or review (PAR): Announcements 
related to areas of increased priority or funding mechanisms for a specific area of science. 
These announcements are usually valid for 3 years from the date of release unless 
otherwise noted. 
 
Sponsored Programs Administration (SPA): A department within a university that 
works with researchers in administering sponsored projects such as federal research 
grants or industry funded research and offers pre and post award services such as grant 
application and budget development, administration of an awarded project and ensuring 
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Chapter 1. Introduction 
1.1. Background 
The National Institutes of Health (NIH) is a federal agency created to support 
medical and health-related research on an international scale. As a division of the U.S 
Department of Health and Human Services (DHHS), the NIH is synonymous with 
funding projects which have contributed to large scale medical breakthroughs both in 
clinical practice and in basic scientific research. The NIH is commonly referred to as the 
agency and had its humble beginnings in 1887 as a single-room laboratory commissioned 
to study the existence of bacteria and its role in infectious diseases as discovered by 
scientists in Europe.1 
Through subsequent years of growth to meet the needs of discovery in healthcare, 
coupled with the availability of federal funding and with Congress’ involvement, the 
agency was formally recognized as the National Institutes of Health in 1930. The agency 
branched out into several divisions as funding became available. Each division caters to a 
specific field of medicine in the pursuit of a more focused pathway of research into 
disease and health. Currently, the NIH is made up of 27 divisions called Institutes or 
Centers. 2  While twenty-four of these Institutes receive federal funding and develop and 
manage their own budgets, all institutes and centers work under the Office of the Director 
and are required to follow DHHS policies and to develop research programs and funding 
opportunities.
                                                          
    1 “A Short History of The National Institutes of Health” National Institutes of Health, accessed February 
2019, https://history.nih.gov/exhibits/history/index.html 





One of the institutes of the agency is the National Heart, Lung and Blood Institute 
(NHLBI) which oversees cardiovascular, respiratory, blood and sleep disorder research. 
Of the units within the NHLBI, the Division of Cardiovascular Sciences is of particular 
interest to the author of this paper, as it supports the study of cardiac and vascular 
diseases which rank as the leading cause of deaths in the world. Research in this area is 
continually evolving, and the NHLBI provides several opportunities for scientists to 
apply for federal funding and support their research ideas.3 
1.2. Statement of the Problem  
Each of the NIH Institutes solicits proposals for research funding several times a 
year based on the agency’s funding cycle. Researchers all over the world are beneficiaries 
of this funding and vie for limited dollars to help advance their scientific work. Each of 
the NIH Institutes release Funding Opportunity Announcements (FOA) seeking proposals 
for review through their pre-defined and transparent peer review process. This peer 
review process includes a Scientific Review Committee appointed to review and score 
proposals received for funding consideration. Researchers that apply to the agency for 
funding can range from postgraduate students to early-careerists, to highly experienced 
scientists. The agency categorizes funding pools and announcements to seek proposals 
from a specific group of applicants (e.g., early careerists, postdoctoral fellows) to 
promote fair competition and encourage all levels of research ideas to compete for 
                                                          
     3 “Division of Cardiovascular Sciences,” National Heart Lung and Blood Institute, accessed February 




financial support. The NIH also uses the standardized form (SF) 424 to ensure that 
relevant and consistent information is submitted for review. The FOA requirements 
dictate which sections of the SF424 form need to be completed. Applicant institutions 
and Principal Investigators (PI) must submit their proposal using the appropriate SF424 
application and federal grants websites such as www.grants.gov. 
Completing the SF424 and constructing a full application can be a challenging 
task for not only the new or first-time applicant but also a seasoned researcher. The 
Sponsored Programs Office (SPA) at the applicant university can assist with the SF424 
completion; however a majority of the information required for submission has to be 
provided by the PI’s research team, and this adds to the challenge. 
The Principle Investigator’s (PI’s) team is expected to write the entire proposal 
which includes the scientific components, project budget and other administrative 
information required to execute the project successfully. Following the FOA and SF424 
instructions are perceived to be a daunting and stressful task as there is very little room 
for error. The NIH provides several tools to assist with grant writing and approaching the 
application process, but it takes dedication and continuity in following all the 
requirements and submitting a complete proposal which is acceptable for review. 
1.3. Project Question 
Successful grantsmanship is an art developed over time. It can take several 
months to write a full proposal that meets the standards for submission and is considered 
review worthy. The PI may begin working on pilot data, building a research team and 
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establishing meaningful collaborations years before the application process is initiated.4 
When working on an NIH application, the PI must decide how much information to 
include on the submission. With page limits and the specific information requested by the 
FOA on different sections of the application, the PI must construct a complete, succinct 
and impactful submission which is distinct and stronger than competing proposals. 
Guidance available for the PI may be located on the internet and through the NIH. It can 
range from being generic to extensive, and it is up to the PI to determine which source is 
most helpful in providing an accurate and complete roadmap towards successful funding.  
The need to share this author’s experience of learning the grant submission 
process from basics, along with tips and feedback received over three years of the 
submission process on the NHLBI FOA PAR-18-407 has resulted in this project being 
undertaken to provide a practical manual covering the grant submission process.   Several 
elements of the manual are common to various NIH grant submission announcements 
since the agency uses the generic SF424 form. However, this manual is best suited to 
complete the scientific and administrative sections of the PAR-18-407 announcement 
released by the NHLBI. The manual includes instructions and tips obtained while 
applying to the NHLBI Division of Cardiovascular Sciences under this FOA, involving 
human subjects’ research in a clinical trial setting. 
1.4. Project Objectives 
The primary objective of this project is to generate a manual outlining the 
approach to a specific NHLBI FOA: PAR-18-407: Clinical Coordinating Center for 
                                                          
    4 Karina Berg et al, : Demystifying the NIH Grant Application Process,” Journal of General Internal 
Medicine, 2007;22(11):1587-95, doi: 10.1007/s11606-007-0301-6  
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Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial 
Required).5 The approach to this involves dividing the application into smaller sections 
while systematically constructing the complete submission. The author uses this NHLBI 
announcement to help explain the different steps in application development. It is the 
author’s objective to create a manual that will include: 
• Instructions on writing the scientific components of the application such as the 
descriptive title of the project, project summary/abstract, project narrative, 
bibliography and references cited, specific aims, research strategy, and the 
statistical design and analysis. Instructions on completing the administrative 
sections of the application include the cover letter, facilities and resources, 
equipment, biosketch for senior key personnel, structure of the project team, 
recruitment of women and minorities, overall recruitment and retention plan, 
single IRB plan data and safety monitoring plan, letters of support required, 
data dissemination and resource sharing plan and study timelines. 
Additionally, the manual will discuss budget development and human 
subjects’ protection as part of the clinical trial required for this FOA. 
• Steps to remain organized when developing the application for submission, by 
identifying sections that can be developed in parallel and those needed to be 
done successively.  
• Sample templates will be included in some sections as examples to assist the 
PI in application development. 
                                                          
    5 Clinical Coordinating Center for Multi-Site Investigator Initiated Clinical Trials (Collaborative 
UG3/UH3 Clinical Trial Required): PAR 18-407,” Department of Health and Human Services, posted date 
26 October 2017, https://grants.nih.gov/grants/guide/pa-files/par-18-407.html  
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• Strategies for efficient utilization of available resources by assigning the 
development of sections of the application to the staff at the university, within 
the research team and those completed by the PI and collaborators.   
1.5. Significance 
The author of the project faced challenges and learned to develop and submit an 
NHLBI grant over three years. There have been instances where a detailed manual like 
the one developed from this project would have provided the author with adequate 
guidance and eliminated surprises during the proposal development and submission 
process. Additionally, the author’s submission has been reviewed by the NHLBI 
Scientific Review Committee twice, thereby providing the author with the unique 
opportunity to include some of the feedback as useful tips for users of the manual during 
their initial submission.  
The NHLBI does not restrict the number of applications it will accept for review 
under this announcement or fund in each cycle, but the chance of obtaining funding after 
high scoring applications are awarded, affect each applicant’s success rate significantly. 
For example, the budget on a high scoring application may take away 60% of the NHLBI 
funding available in that review cycle or fiscal year and allow a few additional 
applications to be funded in the remaining 40% of available dollars. It takes 6-8 months 
for the PI to complete a large application successfully. These challenges underline the 
importance of submitting a proposal that meets all requirements and aligns with the 
NHLBI mission in order to obtain a fundable score in the first round itself.  The author's 
experience completing this process at an accelerated pace within three months with 
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exposure to revising the submission based on reviewer feedback will assist applicants and 
give them a head start on creating a robust application by using the manual. 
1.6. Exclusions and Limitations 
Despite its attempts to be all inclusive, the manual does not assist with submitting 
applications to all types of funding announcements released by the NIH or NHLBI.  The 
NIH’s goal for each announcement is varied and targets a different audience of applicants 
and a range of topics. The application form or the SF424 includes a specific set of 
instructions and further branches out to cater to different categories of applications. 
Attempting to provide a manual to cover all types of announcements and navigating 
through the various SF424 formats is not within the scope of the author’s experience or 
this project.  Readers are encouraged to use the process described herein to investigate 













Chapter 2. Review of Literature 
2.1. Overview of Literature Review 
Information for developing the manual for this project included resources 
available from the National Institutes of Health and its various centers. There are several 
tips on the agency website including examples and videos available to the grant writer at 
no cost. Articles from course work, including interactions with students and Professors in 
the Master of Science in Research Administration Program at Johns Hopkins University, 
have also provided information in developing manual content. Finally, the author’s own 
experiences through interactions with the NIH Program Officer, NHLBI staff 
consultation meeting, working with the applicant university grant administrators, project 
collaborators and revising scientific content developed by the Principal Investigator 
through the three-year application process have provided valuable material for inclusion 
in the manual. 
2.2. Developing Manual Content 
To obtain a broad understanding of the challenges of the application process and 
the various approaches shared by experienced applicants, the author reviewed different 
topics related to grant writing, funding and peer review as follows: 
• The manual covers instructions for an announcement related to clinical trials, 
and it was essential to understand if there were discrepancies in the funding 
rates of clinical trials versus laboratory research applications.  An article on 
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the application and review process of resource grants within the National 
Library of Medicine provided insights in this regard. 6 
•  Several universities have dedicated websites and department pages with grant 
writing tips and institutional policies. The author reviewed the Sponsored 
Programs Office webpage at the University of California at Berkeley for 
information on budget development, and The University of Texas 
Southwestern Medical Center Sponsored Programs Administration home page 
for grant submission processes. 7,8 
• As a research administrator, the author supported an application with an 
annual budget greater than $500,000 in direct costs per year of funding for the 
chosen announcement. The NHLBI process for this budget category required 
an in-person staff consultation meeting with agency officials. Meeting 
experiences from the staff consultation in October 2015 along with guidance 





                                                          
    6 Virginia Massey Bowden, “National Library of Medicine resource grants: application and review,” Bull 
Med Library Association 80(2), April 1992, 
https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC225639&blobtype=pdf 
    7 “Proposals and Awards,” Berkeley Sponsored Projects, UC Berkeley, Accessed February 2019, 
https://spo.berkeley.edu/proposal.html  
     8 “Sponsored Programs Administration(SPA):, UT Southwestern Medical Center, Accesses February 
2019, https://www.utsouthwestern.edu/about-us/administrative-offices/sponsored-programs/ 
     9 “Applications with Direct Costs of $500,000 or More in any One Year,” National Institutes Of Heart, 





2.3. Project Specific Literature Review  
The literature reviewed in support of this project has provided content for the 
manual and has helped the author is organizing the information and simplifying its 
presentation and layout.  
The author began this project by reviewing information related to grants and 
federal funding available on the National Institutes of Health website and assimilated 
relevant information into the manual. The NIH page on grant writing tip sheets has 
videos and information which provide an introduction to the grant writing process. It is 
highly recommended that new investigators review these pages on the website before 
they embark on the application process.10  The National Cancer Institute website includes 
tip sheets that cover grant preparation basics and steps to develop the application.11 
However, this information is available through several links and is not presented in a step 
by step manner, leading to its limited applicability in completing a grant application 
under the PAR-18-407 announcement.  
The video on the NIH website provides an excellent introduction to the NIH 
mission, how to look for grant announcements and the general grant submission and 
review process. The author of this paper recommends that all Principal Investigators 
irrespective of experience level review this webpage initially to help get an idea of the 
work involved in proposal preparation and to plan their approach to completing the PAR-
18-407 application appropriately.  These pages can help with organizing the grant writing 
effort and provide the PI with ideas on preparing a master checklist. 
                                                          
    10 “Grant Writing Tips Sheets,” National Institutes of Health, last updated March 30 2012, 
https://grants.nih.gov/grants/grant_tips.htm  
    11 “Preparing Grant Application,” National Cancer Institutes, Division of Extramural Activities , 
accessed February 2019, https://deainfo.nci.nih.gov/extra/extdocs/apprep.htm  
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The National Institutes of Allergy and Infectious Diseases recommend that the PI 
present the content of the application in a format that is easy for peer reviewers to 
understand the project’s objectives.  Peer reviewers are experts in their respective fields, 
and applicants must take the time to understand their audience and prepare the 
application layout to hold the reviewer’s interest.12  Careful attention should be paid to 
the level of language used; the objective of the proposal and the overall format of the 
application so that the information appears cohesive and follows a logical order.  
The Scientific Review officer chooses members of the Scientific Review 
Committee (Committee) and assigns applications for review. 13  Each Committee 
comprises of a Chair who leads the discussion and moderates the meeting while also 
reviewing any specific applications assigned to them for review. The rest of the 
Committee includes individuals accomplished in the areas of the applications submitted 
for review.  Reviewers receive the application packet approximately six weeks before the 
meeting date and are expected to critique and score the application as well as prepare 
comments for discussion. All Committee members are expected to maintain the 
confidentiality of the proposals and to disclose any conflicts of interest related to 
applications assigned to the Committee. For each application assigned to a Committee, 
three reviewers namely the primary reviewer, the secondary reviewer, and a general 
reader will review the submission thoroughly and be knowledgeable of the entire 
application. The primary reviewer will lead the discussion at the review meeting, and the 
other Committee members will provide feedback and engage in a discussion on the 
                                                          
    12 “Know your Audience,” National Institute of Allergy and Infectious Diseases, last updated April 14, 
2017, https://www.niaid.nih.gov/grants-contracts/know-your-audience  
    13 “Peer Review,” National Institutes of Health, Office of Extramural Research, last updated December 
11, 2018, https://grants.nih.gov/grants/peer-review.htm#Initial 
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merits and drawbacks of the application. The applicant's aim should be to provide enough 
information for the three reviewers to be able to discuss strengths and weaknesses and 
answer any questions raised at the meeting. The application should also be succinct and 
well written for other reviewers on the Committee to grasp the concept in the short time 
they spend looking through the application in preparation for discussion.  The FOA 
includes criteria for review and scoring, and this has dual intent. It helps the PI build the 
application using the review criteria as a guide. It also provides reviewers with a 
framework to assess and score the application by defining information that they should 
expect to find in the submission.  
The Falk-Krzesinski and Tobin article on the different review criteria between 
Federal Grant funding agencies provides a brief comparison of metrics and section 
content on NIH, National Science Foundation (NSF) and National Endowment for the 
Humanities (NEH). While the PI may not find a comparison between all three agencies 
useful in completing an application to the PAR-18-407 announcement, it does add to the 
knowledge on NIH criteria individually and provides a quick snapshot of the main 
components for inclusion in the Research Strategy section of the application. 14 Principal 
Investigators often apply to several federal agencies for funding and the author of the 
article cautions that an understanding of the review criteria for each agency is critical to 
be able to develop application content appropriately for the chosen announcement. If the 
PAR-18-407 submission is not streamlined based on the FOA requirements, it will not be 
scored favorably by the reviewers based on the scoring guidelines provided to them. This 
                                                          
    14 Holly J Falk-Krzesinski and Stacey C Tobin, “How Do I Review Thee? Let Me Count the Ways: A 
Comparison of Research Grant Proposal Review Criteria Across US Federal Funding Agencies,” The 
Journal of Research Administration (46)2, 2015 
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article simplifies each NIH review criteria by translating them into common questions, 
the answers to which can fulfill the review requirements.   
The criteria related to significance translate into the importance of the project 
objectives and must address the current limitation in the chosen area of research that the 
project will address.  In the innovation section of the research strategy, the article 
suggests that the submission include how the proposal stands apart from current practices 
in the area of research by describing new and novel methods and processes.  
For the criteria related to approach, reviewers need to understand the 
methodology and pathway to achieve project goals from the information provided. The 
information should cover the approach on the experimental/ research front as well as the 
supporting and existing data which channelized efforts towards the chosen approach in an 
attempt to enhance current knowledge. 
The pursuit of submitting a grant is associated with several myths shared between 
researchers based on their own experiences with grant writing. Kenneth Henson’s blog 
addresses and debunks some myths associated with the grant writing process and are 
included as grant writing tips in the manual. 15 The blog discusses the myth that fewer 
grants are being funded due to the shrinking pool of federal funds and that only large 
institution with prior federal funding win grants in every cycle. To debunk these myths, 
the blogger states that federal funding remains a viable option to support research 
activities and federal agencies are keen on supporting strong research projects.  
The manual assists with writing a strong proposal to help the PI obtain funding 
successfully in their first attempt. Additionally, institutions and researchers proven to be 
                                                          
    15 Kenneth T Henson, “Debunking Some Myths About Grant Writing,” Chronical Of Higher Education, 
June 26,2003, https://www.chronicle.com/article/Debunking-Some-Myths-About/45256  
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good stewards of federal funding can showcase their success on the facilities and 
resources page or the PI’s biosketch section of the application. The blog also addresses 
the myth that connections are required within the research community to help obtain 
funding successfully. In light of this information from Henson, the manual recommends 
that Principal Investigators establish collaborations with other researchers and constitute 
an Executive Committee to assist with review and feedback on the application.  To 
debunk the myth that meeting the submission deadline is the measure of successful grant 
writing, the manual notes that applying to the right agency and submitting a strong 
proposal should be the primary focus of the PI. The manual notes that submission 
deadlines are non-negotiable and provide instructions on being organized and creating a 
quality proposal within expected timelines. 
The manual aims to help Principal Investigators target specific content for each 
section of the PAR-18-407 application without duplicating information.  The NIH-FDA 
protocol template released in 2017 has been consulted to incorporate instructions related 
to human subjects’ protection, safety assessments and biostatistics in the manual. 16 Upon 
successful funding, these sections from the application can be incorporated into the 
clinical trial protocol and eliminate the need to develop content separately. 
The NIH grant application form SF424 was used as a primary resource in building 
the checklist and application instructions in the manual. As instructed by the NHLBI, 
                                                          
    16 “Clinical Trials E-Protocol Tool and Template Documents,” Office of Science Policy ,National 
Institutes of Health, accessed February 2019, https://osp.od.nih.gov/clinical-research/clinical-trials/  
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specific requirements of the PAR-18-407 announcement were incorporated into the 
checklist and manual.17  
The SF424 general format includes instructions for submitting training, 
fellowship, career development, multi-project, small business, and research applications 
and is extensive and challenging to follow. Since the PAR-18-407 FOA requires the 
completion of the research format of the SF424, the Principal Investigator should access 
this format on the NIH website. This format provides instructions on completing each 
section of the research SF424 application form. The instructions also include web links to 
other areas of the NIH website where information, policies, and guidelines can be 
accessed to complete the grant application. The final pages of the research SF424 format 
include snapshots of the actual forms. While the SF424 is the primary source for 
instructions on completing each question of the application form, instructions within the 
FOA always take precedence if individual sections have different expectations and 
requirements for review. The Principal Investigator is required to assimilate instructions 
from the SF424 and the FOA and complete the application correctly. The author of this 
project has reviewed and compared the SF424 and the PAR-18-407 FOA and combined 
instructions to create the manual and checklist. 
The author of this project also reviewed various locations within the NIH website 
to understand common errors and failures associated with the grant application process.18 
To establish the tone of the manual and cater it to the researcher, the author read blogs 
                                                          
    17 “Research Instructions, Guidance for Research Only,SF424 (R&R) version E” How to Apply-
Application Guide, National Institutes of Health, revised 7 December, 2018, 
https://grants.nih.gov/grants/how-to-apply-application-guide.html   





and websites from other researchers documenting their personal experiences. These are 





Chapter 3. Need(s) Assessment 
 
3.1. Establishing the Need for a Manual 
The NHLBI provides several materials to approach the grant application process. 
However, researchers also acknowledge that the submission process is sometimes 
mastered through trial and error and by obtaining feedback from seasoned and 
experienced peers.  
The author of this project was presented with an opportunity to assist a PI 
affiliated with a local university in submitting an NHLBI grant in 2015. The author had 
no background in submitting proposals and relied on prior research administration 
experience to dissect the application requirements and construct a strong submission. 
Understanding the nuances of grant submission took a considerable amount of time while 
the application was prepared in parallel. The author was simultaneously attending courses 
in the Master of Science in Research Administration Program at Johns Hopkins 
University and was exposed to grant writing tools and knowledge sharing with 
classmates. While students in the program came from varied backgrounds and 
experiences with grant submission, it was a universal theme that not many had attempted 
to submit grants to the NIH or could find tools to help them approach a submission 
systematically. It was noted through discussion boards that most students would approach 
the SPA at their respective universities to initiate an NIH grant submission. In regions 
outside the US, university infrastructure varied to be able to provide such assistance. 
Through these interactions, literature review related to the grant submission 
process and from personal experience, the author chose the topic of writing a manual to 
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guide research applicants through the NHLBI submission process using the PAR-18-407 
announcement as a template. 
3.2. Metrics for Needs Assessment 
The author’s experience while working on the grant application, the assistance 
obtained from the NIH Program Officer and university administrators and examples 
available through the NIH website clearly showed that there are no standalone resources 
available to assist a researcher to complete an NIH application systematically.  The need 
for a step by step instruction manual using an NHLBI announcement was the primary 
metric used to establish the outcome of this project. 
3.3. Resources Aiding Needs Assessment 
The manual is designed to help Principal Investigators complete an NIH PAR-18-
407 grant application. The author chose to obtain guidance from the Principal 
Investigator and collaborators that came together to submit the grant application to this 
announcement at the local university in 2015. The physicians primarily developed 
sections of the application related to scientific content. The author was responsible for 
developing the administrative sections of the application and sought assistance from 
seasoned grants administrators at the applicant university. Input received from 
biostatisticians on the team, the NIH Program Officer and agency Budget Analyst has 
been included as content on the manual. Research associates on the PI’s team at the local 
university who developed and reviewed individual sections of the application also 
provided input into this project. Classmates and Professors at Johns Hopkins University, 
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Master of Science in Research Administration Program have provided material that was 


























Chapter 4. Project Description 
 
This project involves the creation of a manual to apply to the PAR-18-407 
NHLBI funding announcement. The manual includes steps in organizing the PI and 
research team’s time and effort after a funding opportunity announcement is identified 
and before the application process begins.   The manual opens with an introductory 
section which describes the layout of the manual and the information covered to support a 
PAR-18-407 submission. It begins with the process of initiating a discussion with the 
applicant’s university officials on the PI’s intent to apply for NHLBI funding. Discussion 
topics such as the applicant institution’s eligibility to apply to the chosen FOA, its ability 
to support the PI and provide resources during the application process and throughout the 
project period are included in this chapter. 
The manual includes details for the PI to contact the NHLBI Program Official and 
discuss the proposal submission. For project budgets greater than $500,000 direct costs in 
any given year of funding, the manual will provide instructions on preparing for an NIH 
staff consultation meeting by including a sample PowerPoint template with key 
discussion points. The manual will also discuss the process for submitting a revised letter 
of intent incorporating feedback from the staff consultation meeting and obtaining an 
NHLBI acceptance letter to submit a full application.  
The manual also covers instructions on approaching the Food and Drug 
Administration (FDA) for review and determination for the need of an Investigational 
Device Exemption (IDE) or Investigational New Drug Application (IND) for new drugs, 
new indications or expected label changes based on project outcomes. 
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The manual uses the SF424 document and the PAR-18-407 program 
announcement to help construct the full application. In moving through each section, the 
manual describes page limits and the inclusion of content while incorporating feedback 
from previous scientific reviews of an application submitted by the author to this 
announcement. The manual includes instructions for developing the scientific content of 
the proposal for sections such as the specific aims, a project abstract, research strategy, 
biostatistics and project narrative. Descriptions for the administrative sections of the 
application such as the details on facilities and resources, sub-awards for collaborators, 
human subjects’ protection, and project timelines, selecting a single IRB for multi-site 
projects, data management, and dissemination plan are included. A description of the 
details related to completing an NIH biosketch document, Research & Related (R&R) 
budget page, and associated justification is covered in the manual. This section on budget 
development includes possible budgetary items as well as a sample budget template and 
information on indirect costs. 
The manual provides common system errors upon official submission of the 
application and a brief overview of the NHLBI review process. A sample checklist for 
the PAR-18-407 announcement is included to assist the PI and provide a snapshot of the 







Chapter 5. Methodology 
5.1. Methodology 
The approach to gathering content for the manual includes the author’s personal 
experience in completing an NHLBI grant submission and resubmission to the PAR-18-
407 announcement along with materials and discussions with students in the Master of 
Science in Research Administration program at Johns Hopkins University. Several notes 
prepared during the grant submission process, review of the FOA requirements, 
interacting with an academic research organization in developing the proposal, 
consultants and sub-awardees have provided the author sufficient exposure to the 
application process. Discussions on common grant application challenges and review of 
articles in the grantsmanship toolbox completed as part of the course work at Johns 
Hopkins University have also contributed to the development of this manual. Articles on 
the experiences of other applicants provided valuable lessons on avoiding pitfalls.  The 
manual is an assimilation of lessons learned through the years and aims to create a 
comprehensive and easy path for researchers to follow while submitting a winning 
proposal to the PAR-18-407 announcement. 
5.2. Design of the Manual 
The manual includes eight chapters and is designed to assist applicants to 
complete an entire SF424 project application in response to the PAR-18-407 
announcement.  Chapter 1 is an introduction describing the intent of the manual and 
topics covered in the document. 
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Once the PI decides to apply to the PAR-18-407 announcement and before the 
actual application process begins, specific preparatory tasks must be completed. These 
tasks have been covered in Chapter 2 of the manual. This chapter discusses the process to 
approach the Sponsored Programs Office at the applicant university and the importance 
of these initial discussions. The PI should ensure the upper administration at the applicant 
university is supportive of the project idea and that the institution is eligible to apply for 
funding. It also discusses the importance of evaluating the resources required to execute 
the project if the grant funded. The chapter discusses the process of contacting the 
NHLBI through the agency Program Officer and preparing for these initial and 
subsequent contacts as necessary.  For project budgets greater than $500,000 direct costs 
in any given year of funding, the NHLBI requires a staff consultation meeting between 
the PI and key NHLBI department members. The manual guides on preparing for this 
staff consultation meeting which involves a presentation on the project highlights 
followed by an interactive session with questions and critiques. The manual appendix 
includes a PowerPoint template, noting the discussion points for presentation at this staff 
consultation meeting. Guidance on incorporating information and feedback obtained 
during the staff consultation meeting and how it should translate into submitting a revised 
letter of intent and obtain an NHLBI acceptance letter to submit a full application are 
included in this chapter of the manual.  
Chapter 2 discusses the need for creating a steering committee or Executive 
Committee (EC) to lead the proposal. Selecting the right number of people with diverse 
expertise is essential and must be given sufficient time and thought to set the application 
process on the right path. Principal Investigators often delay approaching collaborators or 
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forming an EC. Incorporating appropriate feedback from the members of the EC allows a 
broader set of perspectives to be included on the application and meet the different needs 
of individuals on the Scientific Review Committee. Executive Committee members 
should often meet during the development of the application and discuss data to be 
included, review sections of the application critically and impartially and stay abreast of 
publications and advancement in the proposed area of research. This holistic approach 
prevents essential information and developments from being overlooked which could 
affect scoring during the review process. 
Chapter 2 also addresses the process for contacting the FDA to determine its role 
in providing oversight of the clinical trial required by the FOA. The PI must exhibit due 
diligence with approaching the FDA and discuss the requirements of an Investigational 
Device Exemption or Investigational New Drug application. Most investigators are 
apprehensive about involving the FDA, and completing this step early in the application 
development process prevents surprises during the NHLBI’s review of the grant when 
FDA review is identified to be mandatory. The process of approaching the FDA officials 
and aid in their review by providing appropriate project-related information is covered in 
Chapter 2.  
Vendors and scientific collaborators from outside the applicant institution in 
addition to the PI and his/her staff may be involved in the project. Chapter 2 covers the 
vendor identification process and its role in the development of the grant application. 
Collaborators and vendors are paid with grants funds through sub-awards or contracts 
with the applicant institution. Sub-award paperwork and vendor support letters outlining 
their role, commitment and budget should be included on the grant application.    
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The FOA requires that key project personnel set up an electronic Research 
Account on the eRA Commons website. Chapter 2 discusses the importance and the 
process of account set up and the inclusion of the eRA Commons username on the NIH 
biosketch for these individuals. 
Chapter 2 of the manual completes its discussion on grant preparatory tasks with 
instructions on creating a checklist for this FOA. The checklist allows the project team to 
remain organized and is a quick reference guide to the content required for each section 
of the application. A sample checklist used by the author on the PAR-18-407 application 
is included as an appendix to the manual and can be modified by users of the manual 
depending on the roles within the grant submission team and applicant institution 
requirements. 
Chapters 3 through 6 of the manual provide instructions on completing the 
scientific and administrative sections of the SF424 application and FOA requirements. 
The manual refrains from providing instructions on completing basic information such as 
names and addresses of the applicant institution on the SF424 form. These fields are self-
explanatory and completed by university SPA officials.  
Chapter 3 addresses the scientific components of the PAR-18-407 announcement. 
It begins with the descriptive title and includes the requirements for a project 
summary/abstract and a project narrative. Some of these sections get included in the NIH 
database for access by the general public. Each of these sections has word limits and must 
be written at a specific language level to be incorporated into the NIH database and 
appeal to an audience of non-scientific readers. This chapter also provides instructions on 
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creating the bibliography or references section of the application and includes all articles 
and sources consulted in building the project and the proposal.  
The specific aims and research strategy are important sections of the grant 
application. They should clearly state the objectives, design, and execution plans of the 
project. The final section of this chapter addresses the statistical design and power of the 
project. The biostatistical approach of the project should be reproducible by independent 
biostatisticians reviewing the proposal, and the project should use standard statistical 
tools and methods. This section influences the scope of the project by dictating the 
number of patients to be enrolled in the clinical trial, the size and duration of the project 
and its budget. A poorly defined biostatistical plan can derail the entire proposal with 
reviewers coming away with more questions on the project outcome, than answers it will 
provide as generalizable knowledge to the clinical community. 
Chapter 4 covers the administrative sections of the PAR-18-407 application and 
includes the cover letter, facilities and resources at the applicant institution, equipment 
used on the project, structure of the project team, and the recruitment and retention of 
subjects in the clinical trial. NIH multi-site clinical trials require a single IRB to provide 
ethics oversight to reduce project budget and minimize the timelines for review. Chapter 
4 includes details on identifying a single IRB or obtaining a waiver when more than one 
IRB oversight is required.  
The data and safety monitoring section of Chapter 4 describes clinical trial data 
management including its periodic review and monitoring for safety trends. The 
importance of a data safety monitoring board and the process of data review by this 
committee has been described in this chapter. The chapter also includes a description of 
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the data dissemination and resource sharing plan. The study timelines document on the 
grant submission should describe how and when important project milestones will be 
achieved. The NHLBI needs assurance that project progress will be tracked closely to 
identify delays and implement mitigation strategies. 
 A specific requirement of the NHLBI application is the need to include the 
biographical sketch for project key personnel using the agency’s biosketch template. 
Chapter 4 of the manual discusses the information required on this document and 
provides a sample biographical sketch for the PI as an appendix. 
To submit a strong proposal indicating a supportive group of multi-site 
investigators and collaborators, the FOA requires the submission of letters of support 
from these individuals. Chapter 4 includes instructions on obtaining letters of support and 
provides a sample letter of support in the manual appendix. 
Budget development can take weeks to complete, as it may need to include 
budgets for multiple clinical sites as well as essential components such as salaries, 
reimbursement to participating sites and patients, IRB review, the cost for meetings, 
travel, equipment, and supplies.  The PA-18-407 FOA supports projects for a maximum 
period of 5 years and an extension for the sixth year may be requested by providing 
strong justification. Thus, the budget section of the manual in Chapter 5 covers steps to 
build a project budget for each year of funding. The information related to the base salary 
and fringe and benefits for personnel at the applicant university may be requested from 
the university human resources department. Each individual’s salary support requested 
through the grant must be calculated based on their time commitment to the project. The 
government approved per-diem rates should be used to calculate travel costs and 
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expenses related to project supplies. Sub-award paperwork may be required for 
consultant and collaborator reimbursements. These requirements can add several steps to 
the budget development processes and should be planned appropriately. The manual 
helps assign dollars to common budget line items and provides a sample budget for year 
one that can be duplicated for subsequent years of funding. This is included as an 
appendix in the manual. The grant application also requires a budget justification 
document explaining the dollar support requested for each line item on the project and 
this is included in Chapter 5. 
Chapter 6 of the manual covers information on human subjects’ protection, which 
is required in the application. It addresses risks to human subjects, the need for 
incorporating adequate protection of participants in the trial design, and the risk-benefit 
ratio of subject participation and generalizable knowledge gained from project outcomes. 
Chapter 7 of the manual reviews the actual submission process and standard error 
messages received from the electronic grant submission portal. It provides a brief 
overview of the process and outcomes of the scientific review.  The manual concludes in 
Chapter 8.   
In summation, the manual includes instructions on presenting essential 
information graphically where applicable. The entire layout of the manual has been 
intentionally kept simple and written in a format which is easy to follow. It is intended 
that PI will find all information required to complete each section of the application with 
ease by following the manual. This approach will help the PI to stay organized, focused, 
save time and reduce the chance of missing critical information that needs to be included 
in the proposal. 
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Chapter 6. Project Results and Discussion 
 
The outcome of this project is the creation of a manual to assist Principal 
Investigators in completing an entire application to the NHLBI announcement: PAR-18-
407. Throughout the application process and during discussions with students at Johns 
Hopkins University, the author has been aware of the need for a manual which provides 
step by step guidance on completing an NHLBI grant application. The literature reviewed 
has acknowledged the challenge of planning and completing an NHLBI application. 
While the task of applying for a grant is cumbersome, time spent in finding guidance on 
the application process often results in very little concrete guidance on embarking on a 
logical pathway. 
The author’s first-hand experience has influenced the instructions included in the 
manual. The checklist provided as an appendix to the manual can be used to complete 
each section of the application. By customizing the checklist, it can be used by 
researchers to apply to different NIH grant announcements as well. 
Information on the NHLBI Scientific Review processes available online and 
through discussions with the agency Program Officer has resulted in the manual 
providing instructions to the PI on writing a sharp yet succinct proposal.  
Based on the research done to create this manual and challenges faced from 
experience with the application process, the author of the project has the following 




Recommendation 1: Developing an effective plan for grant writing 
The first step in obtaining funding is to complete all requirements of the 
application and submit it within the specified timeline. The need to juggle various 
commitments and assimilate project components in the application stage is an important 
indicator of the PI’s ability to deliver project objectives once funded. Mismanagement of 
time results in a haphazard and tardy submission and questions the PI’s ability to being a 
good steward of federal dollars. The manual helps the PI to visualize the entire proposal 
and develop its components within the submission deadline. 
Recommendation 2: Writing with clarity 
The grant application should convey the intent of the project, gaps in knowledge it 
will address and how its objectives will be achieved. The cost of reaching the project goal 
should be clearly stated within the abstract as well as detailed in sections of the 
application. The entire submission should be logically presented without information 
contradicting itself. The proposal should pique the reviewer’s interest in the project 
objective and outcome and eliminate ambiguity related to project intent or its execution. 
The manual includes instructions on information to be included within each section of the 
application to help establish a logical flow of content.  
Recommendation 3: Establishing collaborations  
The PI can choose to either collaborate with peers and experienced mentors to 
obtain guidance and feedback throughout the application process or involve collaborators 
as key personnel on the grant application. Building lasting relationships and maneuvering 
through the assignment of project roles with key stakeholders must be initiated early. 
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Clarity on project objectives helps filter feedback from collaborators and mentors and 



















Chapter 7. Conclusion 
 
Grantsmanship is a competitive field and applications which are written well and 
convey project intent, design and outcomes clearly, often receive funding.  With its 
commitment to using federal dollars to support breakthrough medical research, agencies 
like the NHLBI seek to define clear pathways for their review and decision-making 
processes in supporting grants. Soliciting specific content on a grant application ensures 
all submissions include the necessary information needed by the agency for review. 
Therefore, an applicant’s presentation and writing skills play a crucial role to help 
distinguish between competing applications during the review cycle. Reviewers are 
expected to score submissions based on the content provided, and this poses the biggest 
challenge to the PI. The critical step in the long and challenging process of grantsmanship 
is ensuring the right approach is adopted with the help of a dynamic grants administrative 
team. The grant application manual was developed to assist with making this process less 
stressful and more robust.  
The author hopes that using the manual and appendices as a guiding tool will help 
researchers in completing an NHLBI application to the PAR-18-407 announcement. The 
manual seeks to provide general tips to help initiate and complete the grant application 
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Chapter 1.  Introduction 
The National Institutes of Health (NIH) is a Federal agency created to support 
medical and health-related research on an international scale. As a division of the U.S 
Department of Health and Human Services (DHHS), the NIH is synonymous with 
funding projects which have contributed to large scale medical breakthroughs, both in 
clinical practice as well as in basic science research. 
The NHLBI is an NIH Institute which works with scientific projects related to 
cardiovascular, respiratory and blood diseases. The Institute solicits proposals for 
research funding several times a year based on the agency’s funding cycle. Researchers 
all over the world are beneficiaries of this funding and vie for limited dollars to help 
advance their scientific work. The Institute releases Funding Opportunity 
Announcements (FOA) seeking proposals for review through their pre-defined and 
transparent peer review process by the Scientific Review Committee. The NHLBI 
ensures that relevant and consistent information is submitted for review through the use 
of the Standard Form (SF) 424 and submission process. While the form itself has a 
general format, individual sections and components may vary depending on the type of 
funding sought. Applicant institutions and Principal Investigators (PI) must submit their 
proposal using the appropriate SF424 application and federal grants websites such as 
www.grants.gov . 
This manual outlines the approach to submitting a grant to an NHLBI FOA: PAR-
18-407: Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials 
(Collaborative UG3/UH3 Clinical Trial Required). This announcement is associated with 
a companion announcement PAR-18-410: Data Coordinating Center for Multi-Site 
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Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required). Note 
that the NHLBI expects the clinical coordinating center (CCC) and data coordinating 
center (DCC) to function independently of each other in terms of data collection and 
management. This separation is intended to limit the exchange of data between the two 
centers and minimize bias in trial conduct and outcome. The NHLBI also expects the 
centers to work together and execute the project with precision. Therefore, certain 
sections of both applications may have overlapping content to address this requirement. 
The manual works through the scientific and administrative sections of the 
application and provides instructions on the content to be included for each section. It 
assimilates the requirements of the research SF424 form and the PAR-18-407 FOA. 
Completing the basic information of the SF424 form will not be covered in this manual 
as the information collected is standard across all grant submissions to the NIH and the 
questions are self-explanatory. The applicant university staff should be well-versed with 
completing basic information on the form. 
The manual also includes the submission process and possible outcomes of the 
review by the NHLBI. Sample templates for key documents such as the cover letter, 
budget, study timelines, participating site support letters and survey, biographical sketch 
for the PI and project team organization have been provided as appendices to the manual. 








Chapter 2. Grant Application Preparatory Tasks 
 
2.1. Approaching the applicant university research administration 
The PAR 18-407 announcement requires that the application is submitted on 
behalf of a Principal Investigator by their affiliated institution (E.g., University). The 
applicant institution must play an important role in all aspects of application 
development. Through mutually agreeable discussions, tasks involved in this submission 
process may be assigned amongst various stakeholders such as the PI, collaborators, and 
University Sponsored Programs Administration (SPA) associates. However, the Principal 
Investigator remains in charge and is responsible for driving the entire process to 
completion. 
To ensure that all parties involved are aligned with the goals, objectives, and 
timelines of the proposal, the PI should undertake the following tasks: 
• Set up a meeting with university officials to include administrators within the 
Sponsored Programs Administration (SPA) office. This meeting will begin with a 
discussion on the PI’s intent to apply to this FOA and help determine the 
institution’s eligibility to apply for funding.  
• The discussion should cover the project idea and deliverables and identify 
resources required for project execution.  
• Once the decision is made to proceed with applying, a SPA administrator may be 
assigned to assist with application development. There should be agreement on 
the method and frequency of communication between the PI and the SPA 
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administrator: e.g., meeting once a week face to face or via conference call and 
continued e-mail communication or ad hoc meetings/calls between weekly 
standing meetings. These meetings help set tasks to be accomplished each week 
and review their progress. They also provide an opportunity to discuss challenges 
encountered during application development.  
• The SPA administrator will discuss the internal institutional deadlines for 
submission of various components of the application. The administrator will 
review each section and then the entire application to validate administrative 
content and ensure that there are no red flags with the proposal.  
2.2. Approaching the NHLBI 
Once the applicant institution and PI agree on applying to the PAR-18-407 
announcement, the PI should contact the NHLBI Program Officer associated with the 
FOA. This initial meeting is done via conference call, and the discussion should involve 
the following: 
• Details of the project being submitted to this FOA, applicant university details 
such as name and location and the intended deadline for submission. 
• The PI should prepare to ask questions related to the NHLBI submission process 
and specific content to be included on the submission. The Program Officer will 
share information and resources to help the PI prepare for submission. 
• If the Program Officer deems the meeting to be successful and would benefit 
from further discussion, a second meeting involving scientific/ research members 
from within the NHLBI Division of Cardiovascular Sciences will be arranged. 
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Participants at this meeting can include agency biostatisticians, project 
management officials and budgetary experts who are well-versed with agency 
expectations, the review process, and project execution requirements. Feedback 
obtained during these discussions is essential in eliminating multiple rounds of 
edits and revisions throughout the submission process. A member of the PI’s 
team should be designated to take minutes during these meetings. 
• Once the proposal is deemed to hold merit warranting a full application and if the 
proposal expects to spend $500,000 USD or more in direct costs in any given 
year of funding, the Principal Investigator will be invited to a staff consultation 
meeting at the NHLBI office by the Program Officer. 
2.3. Staff Consultation meeting at the NHLBI 
If the PI is invited to a staff consultation meeting due to the project's costs noted 
above, then the first step after initial discussions is to prepare for a staff consultation 
meeting with the NHLBI. This meeting is required to obtain the NHLBI’s approval to 
submit a large grant for review. It includes a formal meeting between key stakeholders 
within the NHLBI Division of Cardiovascular Sciences and members of the Principal 
Investigator’s team and could be arranged in person or via conference call.  
Preparations for this meeting should be thorough and meticulous with a focus to 
highlight the project, ask questions and engage in discussion with NHLBI decision 
makers. The following approach is useful: 
• Draft a Letter of Request including details of the project such as the project title, 
applicant institution, FOA number, project objectives and outcomes, project 
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execution plan, budget for each year of the project, sample size, and duration of 
the project. Include the names of key project personnel and the expected 
application submission date in the letter. Also, include the specific plan for 
sharing project results with the clinical and public audience and how data will be 
shared. Submit the letter to the NHLBI Division Head through the Program 
Officer by the deadline mentioned on the NIH website. The letter of request 
should not exceed five pages, and it is advisable to submit this draft letter 
approximately 24 weeks before the intended full application deadline 
https://www.nhlbi.nih.gov/grants-and-training/policies-and-
guidelines/applications-with-direct-costs-of-500000-or-more-in-any-one-year  
• Within a few weeks of receiving the letter of request, the NHLBI program 
Officer will notify you of a decision on whether the agency is willing to allow the 
application to be submitted. If you are selected, you and the research team will be 
invited to a staff consultation meeting.  
• If the meeting is in-person, identify 2-3 important members of the project team to 
accompany the PI to the meeting location. Additional team members may be 
invited to attend and support the project via a conference call. The NHLBI 
Program Officer can help with setting up a conference call number and 
coordinating meeting logistics. 
• Staff consultation meetings are usually 60 minutes in length. Various members 
from the NHLBI attend the meeting depending on availability. The Program 
Officer and Scientific Review Officer assigned to the FOA are generally present. 
Additional members such as the Head of the Division of Cardiovascular 
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Sciences, the NHLBI biostatistician, officers and administrative personnel such 
as budget experts and project management experts may be present. These 
individuals are well-versed with the application process and agency policies as 
well as review scientific committee feedback and therefore a well- prepared 
presentation from the Principal PI is a must. 
• Prepare meeting slides to present project details for approximately 30- 35 
minutes. Ensure content is precise but comprehensive and covers topics included 
on the letter of request previously submitted.  
• Handouts may be provided, however the NHLBI appreciates the careful 
expenditure of dollars even in the pre-submission phase. 
• Once the slide set is ready, the PI should request collaborators and SPA 
administrators to review and provide feedback as different perspectives can help 
make the presentation stronger. A sample template for the slides is provided in 
Appendix II 
• After the presentation by the PI, the rest of the hour includes a discussion 
between members present at the meeting. This involves questions from the 
NHLBI staff on the project objectives, execution plan, budget as well as project 
size and biostatistics. The PI should be prepared to answer questions and explain 
the approach to the project. Suggestions may also be put forth by the NHLBI 
members. The PI should be open to feedback and criticism, and a designated 
member should take detailed notes during the discussion. This meeting is also the 
opportunity for the PI to ask the agency members questions and seek clarification 
on the submission process or the proposal. 
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• Following the meeting, the PI must modify the letter of intent incorporating the 
feedback received and resubmit to the NHLBI not more than 12 weeks before the 
intended application submission deadline. The NHLBI will respond within two to 
six weeks of the receipt of this letter with a decision to allow the applicant to 
submit a full proposal. This decision is released in the form of a letter that 
includes details of the project, and the budget cap for the project. Note that the 
time available between receipt of this acceptance letter and the submission 
deadline for the full proposal can be as short as six weeks and hence the PI must 
remain in contact with the Program Officer to ascertain the agency’s 
receptiveness to receiving a full application. The PI should begin preparing 
content for the full application simultaneously while the decision is awaited. 
• Once the official invitation letter is received, the PI should review the contents of 
the letter to ensure the information included is accurate. Any discrepancy should 
be addressed immediately with agency staff and a final letter obtained. This letter 
must be included on the final submission, and it is crucial that it reflects the 
correct information. Note that receipt of a staff consultation or a letter of 
acceptance does not guarantee funding. It only allows the submission of a full 
grant application for consideration by the scientific review committee and the 
NHLBI. 
2.4. Approaching the FDA 
If the proposed project will include investigational drugs or devices or new 
indications of marketed products, the FOA recommends that the pre-IND or IDE meeting 
with the FDA be completed before the application is submitted for peer review. The 
14 
 
outcome of this meeting with the FDA must be included in the NHLBI application. If the 
FDA determines that a full IND or IDE application is required for their review, 
information on how this will be accomplished, and the expected its timeline must be 
included in the NHLBI submission. The pre-IND or IDE discussion with the FDA can be 
initiated as follows: 
• Create a project synopsis document including key details of the clinical trial. 
Most components in this document will include information from the letter of 
intent and the NIH staff consultation slides. Ensure the document sent to the FDA 
clearly states the request and outcome being sought from their review. Submit 
this document to the FDA using the appropriate contact listed on the agency 
website and follow-up with a phone call. The FDA is an approachable agency 
and is willing to schedule a conference call to discuss the project. Due to 
competing priorities and time constraints, this process could take a few weeks, 
and it is essential to contact the FDA early in the application process. If the FDA 
determines the project does not require an Investigational New Drug (IND) or 
Investigational Device Exemption (IDE) application, the agency will confirm the 
same via a letter faxed to the PI. This letter can be included with the grant 
submission packet to indicate to the reviewers that due diligence has been done in 
consulting the FDA. If the project idea changes during the development of the 
grant application, the FDA may need to be consulted again to confirm the 
exemption carries through. 
• If the FDA determines that an IDE or IND application is required, further 
consultation with the agency should be scheduled, where a timeline for 
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submission and approval is discussed. This information and the plan to obtain full 
approval from the FDA should be included on the grant. The NHLBI expects to 
review these timelines before a funding decision is made, to ensure the project 
start will not be delayed once funding is released.  The PI must also confirm with 
the NHLBI Program Official that the proposed timeline is reasonable and 
acceptable to the agency in consideration for funding.  
2.5. Setting up an Executive Committee 
An Executive Committee (EC) functions as a steering group for the project. This 
committee should be formed as soon as discussions with the NHLBI Program Officer 
begin. The EC should be comprised of experts in the field of the project topic. Depending 
on the size of the project, the number of committee members may vary. The committee is 
led by the Principal Investigator and can include 4-5 physicians, the lead biostatistician 
and the project manager. At least two members of the EC should be present in person 
along with the PI at the NHLBI staff consultation meeting, and additional EC members 
can be invited to join the staff consultation meeting by phone.  
Once the decision is made to proceed with submitting a full application, the PI 
can ask members of the committee to participate in writing or reviewing application 
sections. Regular EC calls should be held to discuss the progress of the application, 
content for inclusion, any challenges foreseen with project execution or to obtain 
feedback from experts on the Committee. The EC members contribute as the first round 
of critical reviewers and accepting their viewpoints for discussion can help strengthen the 
application significantly. If any of the EC members are to be compensated for their time 
on the project through the grant budget, a sub-award should be initiated with their parent 
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institution. Note that EC members may not always be considered key personnel on the 
project based on their contributions and commitment and the need to submit their NIH 
biosketch should be evaluated accordingly. 
 2.6. Collaborators and sub-awards 
At the initiation of application development, project collaborators within or 
outside the applicant institution may be identified. 
Collaborators outside the applicant institution: 
• Vendors who can provide services or products should be identified through a 
Request for Proposal (RFP) process, and the SPA administrator assigned to the 
project can aid in this regard.  
• Once responses to the RFP are received, vendors and services should be 
finalized, and representatives from these companies should be included in the 
application development process. Vendors often provide information about the 
product and its role in enhancing the project being considered for funding.  
• Obtain a budget and support letter from the vendor to include on the grant 
application. 
• For collaborators at other institutions, the SPA will initiate sub-award paperwork 
between both institutions and this will include the scope of work and acceptable 
budgetary allocations. Note that collaborator budgets have specific requirements 
on how they are included as direct and indirect costs on the final application. 
Once a grant is funded, significant deviations to sub-award allocations from the 
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initial submission are rarely acceptable to the NHLBI. Therefore, the PI and 
applicant institution must negotiate and reflect sub-award costs accurately. 
Collaborators within the applicant institution: 
• Budgetary allocations for collaborator salaries commiserate with their time and 
effort on the project must be discussed with the SPA administrator. Institutional 
policies may limit collaborator participation to ensure their institutional 
responsibilities are balanced. Misrepresentation of these areas on the grant 
application can become significant findings during project audits and affect an 
institution and individual’s ability to apply for future funding or participate in 
other projects. 
2.7. eRA Commons system accounts 
This FOA requires that the PI and all key personnel have eRA Commons accounts 
set up before the application submission. Most universities have an institutional account 
and employees must request their individual account through the university. The PI and 
key research team members must initiate account set up before the application process is 
initiated. It could take several weeks for account set up, and the process should run in 
parallel with application development. Once the account is set up, users obtain their login 
credentials (username and password) via e-mail. This account user name is required to be 
included on the NIH biosketch and submitted with the application.  
The eRA Commons account will also reflect application submission status, its assignment 
to a scientific review committee and meeting dates, scores obtained and the review 
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summary statement. The agency does not send status updates by e-mail; hence access to 
the eRA Commons account is essential. 
2.8. Creating a checklist 
While the letter of intent is under review with the NHLBI, it is recommended that 
the PI begin working on the full application. A submission checklist should be created to 
include all components of the application from the FOA and SF424 form. The effort 
expended at this stage in reviewing all materials and guidelines related to the FOA and 
assimilating important points in a checklist is invaluable. A sample checklist is included 














Chapter 3. Scientific components of the application. 
Most sections of the scientific components of the application are written 
separately and uploaded as PDF documents in designated sections of the final SF424 
application form. The PI should be cautious in keeping track of the required formatting 
and page limits for each section, as disregarding these requirements can automatically 
disqualify the application once submitted. 
Page limits and formatting instructions are included within each section of this 
manual and can also be found on the NIH website at https://grants.nih.gov/grants/how-to-
apply-application-guide/format-and-write/format-attachments.htm  
3.1. Descriptive title of project 
• The project title must be 200 characters in length to include punctuation and 
spaces. The title will be typed directly on to the SF424 application. An acronym 
can be included, and this counts towards the character limit.  
• Since this FOA is part of a cluster and paired with the PAR-18-410 
announcement, the project title should include the number of the application in 
the cluster. It will help the NHLBI pair the correct number of applications 
together for review, e.g. A Randomized Double-blind study to determine the 
bleeding effects of (Drug Name) in Geriatric patients-1/2. 
3.2. Project Summary/Abstract 




• The content should include a brief description of the project to be undertaken and 
provide an accurate snapshot for readers to understand the what, why and how of 
the project.  
• It should describe the long-term objectives, health relatedness and relevance of 
the project to the NHLBI mission. 
• It should be written in language that caters to the non-scientific community and 
should not use the first person. Specifically, the information should include 
project objectives, size and duration, and measurement of outcomes.  
• Do not include budgetary or confidential information on the abstract. This section 
will be placed in the NIH database and accessed by the public. 
3.3. Project Narrative 
• This section is submitted as a PDF attachment uploaded to the SF424 application.  
• It should describe the public health relevance of the research project in 3 
sentences. If funded, this section will be combined with the abstract for public 
release. 
3.4. Bibliography and References cited 
• There is no page limit to this section.  
• All materials referenced and relevant to the project must be included in this 
section. If the article referenced falls under the Public Access policy, NIH 
Manuscript submission reference or PubMed Central (PMC) ID if available 
should be included. For articles that are in publication, indicate “PMC Journal -in 
process” against the reference. 
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• For articles that do not come under the Public Access Policy, the URL or 
PubMed ID (PMID) may be included along with the full article reference.  
3.5. Specific Aims 
This section is significant as an introductory piece to the project and must be 
compelling to pique the interest of the reviewer. It should include: 
• A single page PDF attachment uploaded to the SF424. 
• The content should include a concise description of the project goals, the 
objectives and expected outcomes and the impact of the results on the associated 
field of research.  
• Identify if the project is testing a hypothesis, proposing a solution to a critical 
problem or providing evidence that could impact clinical practice. 
 3.6. Research Strategy 
The research strategy is the foundation of the entire project. As noted in this 
section, the content of the research strategy describes the scientific intent of the project 
such as the primary and secondary objectives, the trial design, key components of the 
clinical trial such as inclusion/exclusion criteria and the processes to be undertaken. The 
sections of the research strategy provide insight and framework for each area of the 
project. It is advisable that this section be written first before other content of the 
application is developed. Spending adequate time on the research strategy is critical to 
developing a robust section which in turn sets the tone for the rest of the application. 
The research strategy should be developed as a 12-page PDF document uploaded 
to the SF424 application. The section provides the PI with an opportunity to include key 
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aspects of trial conduct and human subject participation and must not duplicate 
information provided elsewhere on the proposal. The FOA requires this section to be 
broken down into subheadings and each subsection has specific instructions as follows: 
a. Significance: Explain the clinical trial importance and clearly state the question 
to be answered or the objective of the project. It should include the methods 
employed to test the hypothesis or meet the project objectives. The description 
must clearly explain the relevance of the project to current problems and the 
solutions proposed. The information should include why the project outcome 
would be relevant to the clinical community despite possible advancement in the 
field at the time of project results being available. Describe how the project 
results will advance clinical care to improve health care decisions and influence 
current practice trends. 
b. Innovation: This section must describe how the project seeks to be innovative in 
its approach and execution. New ideas or the use of current resources through an 
innovative approach should be explained here. This section should address 
expected challenges with testing this innovative approach and the plan to 
overcome them, as an indication that the approach has been whetted thoroughly.  
c. Approach: Support or pilot data available from prior research which helped build 
the hypothesis and objectives of the current proposal is described in this section. 
It is advisable to include statements on how existing data has shaped the 
approach to executing the project. The approach to the project must bridge the 
path between pilot data and project outcomes to assimilate into the objectives of 
the proposal.  The information can be included in subsections as follows:  
23 
 
• Experimental approach: 
i.  Include the critical features of the project which have not been 
described in other sections of the application such as the human 
subjects’ protection section. This includes details of the rationale for 
the research hypothesis and trial design (e.g., pragmatic, randomized, 
open-label.). Ensure that the definitions used to describe trial design 
are consistent throughout the application  
ii. Include details of the target population under study and any specific 
characteristics that influenced the selection of this study population. 
For example, describe the age of eligible participants, the primary 
inclusion characteristic and how this group is best suited to support the 
expected outcomes of the project objective. This is the primary 
inclusion criteria for a clinical trial: e.g., subjects > 30 years of age 
who have suffered a Myocardial Infarction within three months prior 
to screening. 
iii. Include the research processes to be employed in the execution of the 
trial. This commonly includes a description of in-person clinic visits, 
phone contacts, medical chart reviews, questionnaires to be 
administered, psychological tests, lab tests and other procedures 
required in the trial. Any non-traditional study methods such as use of 
online applications should be described briefly.  
iv. The clinical trial required for this FOA should follow Good Clinical 
Practices. Implementation of GCP concepts and monitoring of 
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compliance should be described briefly. The Human subjects’ 
protection section will include additional details of this concept and 
the information between these sections should not overlap. 
• Supporting Data: Pilot data or preliminary work accomplished by the PI or 
other researchers on the project topic should be described. Only relevant 
research studies that supported and influenced the development of the current 
proposal must be included. The NIH has a definition of clinical trials found 
here: https://grants.nih.gov/policy/clinical-trials/definition.htm . If the 
proposed project meets the definition of a Phase III Clinical Trial, information 
on the analysis of the primary objective and any subgroup analysis should be 
described. Note that details of biostatistical considerations will be included in 
a section specifically dedicated for this information on the application. 
3.7. Statistical design and power. 
 
This section has no page limit and is uploaded as a PDF document on the SF424 
form. The outline for this section should be in place at the time of the NHLBI staff 
consultation meeting and modified based on feedback received at the meeting. The 
statistical design of the study determines the size of the project by influencing the sample 
size, project budget, and execution timeline. For multi-site projects, the sample size will 
help determine the number of sites required to complete the project on time. The 
statistical design and plan should include the following description: 
• Computation of the required sample size and the assumptions made to arrive at 
this number, including the statistical power. 
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• Acceptable dropout rate to account for incomplete data, patients who withdraw or 
lost to follow-up before trial completion.  
• Analysis plan for the study objectives: primary, secondary, tertiary, exploratory 
endpoints. 
• Software and standard statistical methods to be used. 
• Any interim analysis to be conducted and the time points in the project to achieve 
this, its possible outcome and the plan for action depending on interim analysis 
results or delays in reaching project milestones. 
• If the interim analysis process and results will be blinded or if unblinded data will 
be used. 
• Stopping rules for the clinical trial when certain thresholds are met. 
The statistical analysis section will help develop the statistical analysis plan and 
the case report forms (CRF) when the project is funded. The CRF’s are used by 
participating sites to collect and submit trial-related data. The statistical analysis plan is 
used by the biostatisticians and data management group to analyze data.  
Given that the foundation of the project’s success is based on the statistical plan, 
it is critical to get this section correct at the very beginning. Note that the statistical 
analysis plan should be described in a manner that independent statisticians are able to 
understand and replicate the plan. The NHLBI statisticians pay close attention to this 
section and often question why other approaches have been excluded. The study 




Chapter 4. Administrative sections of the application 
4.1. Cover Letter 
A cover letter is to be included with the application and developed as follows: 
Type the cover letter on the applicant institutional letterhead and address it to the NHLBI 
Division Chief from the PI. Include the following information on the letter 
1. Title of application and FOA number 
2. The name of the applicant institution and the PI’s name and contact information 
3. Statement if any component of the sub-award budget is not consistent in each year of 
funding, e.g., if a collaborator will only be compensated for three years of the five 
year project. 
4. If the application has been approved for direct costs greater than $500,000 in any 
given year of funding, include a statement regarding this approval and attach the 
NHLBI approval letter to the application. 
5. If a video is to be submitted with the application, include this information on the 
cover letter. Failure to include this information can result in the video not being 
included in the review. 
6. If the project will generate large scale human or non-human genomic data per the 
NIH Genomic data sharing policy, this should be mentioned in the cover letter. 






4.2. Facilities and Resources 
This section is written and uploaded as a PDF document and does not have a page 
limit. It should describe the facilities at the applicant institution in relation to project 
conduct. It is advisable to start with a brief history of the institution along with the central 
departments available to support the research project (SPA, clinical departments, research 
unit, and infrastructure). If the institution has prior experience administering federal 
grants with success and is recognized for its research accomplishments, it would be 
appropriate to include this information on this section. The section should include the 
following information: 
• The PI should narrow does facilities available for the conduct of the project. For 
example, clinical trials can include how patients will be seen and resources 
available to screen and support patients throughout the trial. If medications are 
used, the availability of a dedicated and access restricted space or pharmacy to 
control the study product should be included.  
• Office space with equipment such as computers, printers, fax capabilities, storage 
space for paper charts and online research records should be described.  
The objective of this section is to inform the reviewers that the applicant 
institution has resources to support the project or has a plan to acquire necessary facilities 
if the project is funded. If resources are to be acquired, this section should describe a 
timeline for acquisition, and assure the reviewers that time will not be spent on 




For multi-site projects, this FOA expects facilities and resources available at the 
various participating sites to be included in the application. The PI can obtain this 
information by drafting a template letter which is sent to all participating sites. Each site 
can customize the letter and include their site-specific resources available to support the 
project. Alternately, this information can be collected through a participating site survey. 
The survey includes questions related to the availability of facilities and resources 
relevant to the proposed project at each site. This survey is sent to all participating sites, 
and the responses are tabulated and included on the application under this section.  
4.3. Equipment  
This section is uploaded as a PDF file and does not have a page limit. It should 
include information about equipment already available for the project and those that will 
be purchased using project dollars. Office equipment such as computers and printers 
should not be listed here. List equipment specific to project conduct, e.g. freezer, pumps 
for intravenous medications, etc. 
4.4. Senior Key Person profile and Biosketch: 
The NIH has a specific biosketch format limited to five pages and is available at: 
https://grants.nih.gov/grants/forms/biosketch.htm  
A biosketch must be submitted for all Senior Key Personnel on the project. Senior 
key personnel are individuals that play a significant role and contribute to the scientific 
development and administrative execution of the project. For this FOA, a non-fellow NIH 
biosketch format must be used. Also note, the template has an ‘approved through’ date on 
the top right side of the page. Ensure that the template remains valid through the date of 
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the grant submission. In some instances, the NHLBI may release a notice stating that 
templates that are expiring in the year of the application are valid through certain 
submission cycles. The PI must pay attention to these details and request all key persons 
submit their biosketch on the correct template.  
The template has four sections from A through D. Complete the key personnel 
name, including the eRA Commons username and position title on the first page and 
provide details of education with dates, degree obtained and the institution of granting the 
degree. 
In section A, the key person should provide a personal statement. While this 
section can be used to outline significant accomplishments, since the overall biosketch is 
limited to five pages, section A should be used to describe the collaborator’s previous 
work, their interests, and accomplishments in the research related to the proposed project. 
Only four citations from the key person’s work relevant to the project can be included in 
this section. This section is often modified depending on the role of the key person and 
associated project when an NIH biosketch is required for any proposal. 
Section B captures the positions and titles of the key person. They should be 
listed in chronologic order and formatted neatly for easy readability. Honors related to the 
area of the proposed project should be highlighted in this section. 
Section C requires listing five of the key person’s most current contributions to 
science. The scientific contributions that are related to the proposed project should take 
precedence. Writing a few sentences about each contribution and how it leads to the 
proposed area of grant submission is an excellent way to show continuity in one’s 
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contributions to the specific topic. For each contribution, the biosketch allows up to four 
publications. If no significant contributions are to be included, the key person should list 
“NONE” under section C. Finally, a link to the complete list of the key person’s 
published work should be obtained from the NIH MyBibliography page and provided at 
the end of section C. 
Section D requires the key person’s research support and ongoing funded projects 
to be listed. List the project title, years of funding support and the role of the key person 
for each project. List the most recent ongoing funded projects first followed by those that 
have been completed. The goal of this section to highlight the versatility and success of 
the key person in obtaining research funding, completing projects and validating for the 
NIH that there is no overlap in funding sources on the proposed project. A sample 
biosketch for the Principal Investigator has been included in Appendix IV. 
4.5. Structure of the project team 
This document is uploaded as a PDF attachment on the SF424 form and does not 
have a page limit. The information included here should describe how the entire project 
team is set up to drive the clinical trial towards success. 
• It is advisable that the document begins with a graphical representation of the 
different positions held by the project management team (Appendix V). The 
representation should be a hierarchical flowchart which depicts the relationships 
between the various positions and ultimately reports up to the PI. Note that the 
representation should be simple and easy to follow but comprehensive to show 
the different groups that are working together on project execution. 
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• Following the graphical representation, the details of each position function and 
names of the individuals fulfilling those roles should be provided. Providing 
these details is indicative of the thoughtful planning and preparedness of the 
project team to initiate the grant as soon as it is funded. Reviewers do not like 
position descriptions be listed as to be determined (TBD) unless the position 
requirement is unique to the project and will be filled upon successful funding. 
The role of the EC and its members should be described in this section as well.  
• The communication and coordination required between the different working 
groups such as project manager, biostatisticians, data management, the 
monitoring group, EC, and vendors should be clearly described.  
• If the data coordinating center accompanying this cluster FOA is a separate 
entity, the relationship and coordination between the CCC and DCC should also 
be described.  
Overall, a task grid outlining the processes overseen by each role on the PI’s team 
is helpful for the reviewers in understanding project management and execution. 
4.6. Recruitment of women and minorities 
The NHLBI has been an advocate of ensuring women and minorities are 
adequately involved and represented as research participants so that project outcomes can 
be generalized to these populations, especially if it involves clinical outcomes. The PAR-




• Recruiting efforts to be implemented such as working with women’s groups, or 
practices that focus on women’s health and communications with outreach and 
support groups that work with minorities.  
• The section should also include an estimate of women and minorities that are to 
be recruited in the study and if subgroup analysis or outcomes are expected to 
vary based on the proposed objectives. Pilot data on how the expected sample 
size related to the inclusion of women and minorities was derived should be 
included 
• If certain groups such as from the vulnerable population, pregnant women or 
specific ethnic groups are to be excluded in the project, this should be disclosed 
with substantial justification. 
4.7. Recruitment and retention plan 
This section of the application is completed as a PDF document and uploaded on 
the SF424 form. It should describe the plan to recruit subjects in the clinical trial to meet 
the overall enrollment goals. Specifically, the plan should provide: 
• A breakdown of planned enrollment by each year of funding should be included 
to help the reviewers envision the progress of the trial and when data for the 
evaluation of primary and secondary trial objectives and interim analysis will 
become available.  
• Through the participating site survey (Appendix VI), the expected enrollment at 
each site per month and the expertise of individuals responsible for recruiting 
subjects, screening and consenting at these sites should be described. The FOA 
33 
 
requires a table of the sites identified to participate in the clinical trial with their 
commitment in terms of enrollments in each month of the study  
• For special populations (e.g., rare disease proposals), women and minorities, the 
use of community or patient advocacy groups to assist with recruitment should be 
included. If vulnerable populations are included, a plan to protect their rights and 
welfare throughout participation is required. 
• Primary and back up strategies, along with plans to evaluate study progress in 
terms of subject recruitment and retention should be described. For interventional 
clinical trials, the plan to obtain subject vital status especially for those who 
withdraw or drop out of the study prematurely should be in place.  
4.8. Single IRB plan 
To consolidate and streamline ethics review and reduce study start-up timelines, 
the NIH requires all non-exempt human subjects research multi-site applications 
submitted on or after January 18th, 2018 to identify a single central IRB which will 
provide oversight of the project and participating sites. This requirement is extended to 
the PAR-18-407 announcement and the plan to include a single IRB must be submitted as 
a PDF attachment and has no page limit. The PI must follow the steps noted below to 
identify a single IRB for its services and include details on the grant application. 
• Early in the application development process, the PI should reach out to several 
central IRBs that can provide the required service. Details regarding the proposal, 
duration of the project, number of sites, number of subjects and estimated 
timelines should be provided to each IRB to allow them to evaluate if their 
services are appropriate for the project. The IRB will also provide an estimate of 
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costs for its services. The research team should obtain a cost breakdown for each 
year of funding.  
• Some IRBs are willing to share a list of trial sites that accept their review which 
helps with evaluating the most feasible IRB to include on the project, based on 
the sites participating in the clinical trial. 
• On the survey sent to sites for information on their facilities and resources, a 
question related to the acceptable central IRB review for the site should be 
included. These responses will also help in the decision of choosing the single 
IRB for the project. 
Based on information received, the EC, PI and university SPA administrator must 
identify the single IRB of choice.  A letter of support from the chosen IRB must be 
obtained stating their commitment to providing oversight to the project and noting their 
budget for each year of funding. 
Additionally, this section must include details on how communications between 
the IRB and sites will be handled. These would include initial submissions, event 
reporting, deviation reporting, and annual renewals. A clear plan of implementing IRB 
decisions must be described to ensure sites remain in compliance with human subjects’ 
protection. For sites that will work with the chosen IRB, information related to their 
willingness to execute a reliance agreement to accept the central IRB review for the 
project must be included. The actual reliance agreement should not be included in the 
grant submission and can be executed between the site and the central IRB once the 
project is funded. For sites that are unwilling or unable to accept the chosen IRB for 
oversight, an explanation must be provided with an alternate plan for oversight at these 
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trial locations. The NHLBI will evaluate if the justification provided is sufficient to 
exempt these sites and allow a different IRB to review the project at these sites. 
4.9. Data and Safety Monitoring Plan 
The PAR-18-407 FOA requires the conduct of a clinical trial and human subjects 
enrolled in the trial must be protected adequately. Plans to oversee subject protection 
through the evaluation of data and defined safety parameters are outlined in this section 
and submitted as a PDF document uploaded on the SF424 form. The NIH requires a Data 
Safety Monitoring Plan (DSMP) commiserate with the risks, size, and complexity of the 
trial to be included as well. 
• This section should define the expected adverse events from trial participation 
and how they will be evaluated, recorded, reported and analyzed. The process to 
train site staff on identifying events and the reporting pathway should be 
described  
• Once the site reports events, the process for the project team to review and 
evaluate these events and track trends must be described.   
• Include what data points will be monitored from a safety standpoint.  
• Depending on the size of the trial, a Data Safety Monitoring Board (DSMB) will 
be constituted upon successful funding and in collaboration with the NHLBI. 
This Board will consist of independent physicians, biostatisticians, and experts in 
the field of the proposed project. The NIH will appoint members of the Board; 
however, this plan must describe the composition of the board as proposed by the 
PI without naming specific individuals.  
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• The frequency of the board meetings including data they will review, the format 
of meetings and data review (online versus in person and blinded versus 
unblinded data) must be included. Stopping rules depending on event rates or 
from meeting pre-defined thresholds should be described briefly to show thought 
has been given to protecting subject safety. The DSMB will decide the final 
stopping rules and acceptable safety thresholds which will be incorporated in the 
Committee DSMB and incorporated in their charter at the beginning of the 
project 
• The PI and EC will enforce the DSMB’s decision on trial modifications and 
stopping rules.  It is important to mention in this section that the DSMB will 
function independently and members will not have a conflict of interest with 
study conduct. 
4.10. Letters of support 
Letters of support must be included from the following individuals and groups: 
1. Key stakeholders such as members of the EC: The letter should be addressed 
to the NLHBI Division Chief and outline the individual’s support to the project, 
their time commitment and the specific role played by the EC member on the 
project. If an EC member bills a consulting fee for their role on the project (i.e., 
not salaried through sub-award paperwork), they should mention their time 
commitment and hourly rate on the support letter. 
2. The PI’s institutional department chair or applicant institution 
administrators: The College Dean, Department Chair and other official 
university administrators should also provide a support letter if possible. This 
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letter will state that the applicant institution is aware of the scope of the project, 
has evaluated its ability to provide the required resources and is willing to 
support the project if funded. 
3. Vendors: Vendors supporting the project such as the Central IRB should also 
provide a letter of support along with their budget information and clearly stating 
their role and capabilities in supporting the project. 
4. Individual site Principal Investigators or institutions: the PI at each site on the 
multi-site clinical trial should provide a letter of support stating that they have 
evaluated the project, the inclusion/exclusion criteria for patients, reviewed their 
patient population and resources, and are confident of successfully participating 
in the trial if funded. Each site support letter should also include an approximate 
number of patients the site can enroll each month. It would be useful to note how 
each site arrived at this contributory number to assure the reviewers that the 
commitment is realistic. Common examples include monthly enrollment 
estimates obtained through medical chart review or the number patients seen at 
the site recently with the condition under study.  
5. Consultants: It is advisable to collect a letter of support from the consultant 
outlining their experience to contribute to the project and clearly stating their 
time commitment and hourly billable rate 
It is advisable for the PI to draft letters of support templates and send those to the 
participating sites along with the survey, asking them to place the language on 
institutional letterhead, enter site-specific details, and sign and return the letter to the PI. 
This approach is successful when compared to asking sites to write their support letter for 
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the project. Note that the process to obtain support letters from all participating sites can 
take a few weeks and should be done in parallel with other application processes. A 
sample letter of support template has been included in Appendix VII of the manual. 
4.11. Data dissemination plan/Resource sharing plan 
Since the NHLBI is a federal agency supporting the PAR-18-407 announcement 
through taxpayer dollars, it is crucial that the outcome of the research project is made 
available to the general public as well as researchers worldwide. The data enables other 
researchers to build on the project idea and explore it further, develop alternate 
hypotheses or serve as pilot data for subsequent projects. For projects with direct costs 
greater than $500,000 in any given year of funding, the NIH expects its Data Sharing 
Policy will be followed. These guidelines can be found at 
https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm.  These 
guidelines must be carefully reviewed and incorporated into this section of the PAR-18-
407 application. 
The NIH expects that data used in the analysis of the project objectives will be 
made available to other researchers. This requirement goes beyond the sharing of 
aggregate data. Protected health information should be removed from any datasets before 
being shared. The project EC should discuss the timeline for data release along with the 
data formats to be made available. Data should be available for sharing before the 
primary findings are published. The project team can propose to release the required 
dataset in different formats such as de-identified data by geographic location, gender-
based data, and dataset with limited identifiers. The process for requesting datasets must 
39 
 
also be described to include the need for any agreements to be executed before a 
requestor is granted access to the study data.  
4.12. Study timelines 
This section is written and uploaded as a PDF document on the SF424 form and 
has no page limit. The section should begin with a description of the overall timeline of 
project execution from funding to final study close-out and publication.  It should provide 
a breakdown of the important milestones to be achieved in each year of funding. This 
FOA is divided into a UG3 and UH3 phase. The UG3 phase covers the first year of 
funding. The FOA has specific requirements that must be met in this first year/UG3 
phase before the NHLBI will consider funding the remainder of the project. This 
approach has become prevalent with the NIH in recent years to mitigate the risk of 
projects failing to meet their primary goals or requesting project extensions and 
additional funding beyond what was initially approved. For the PAR 18-407 
announcement, the NHLBI expects the following processes to be completed in year 1 or 
the UG3 phase of funding: 
• Documents such as the study protocol, informed consent form, data management 
and dissemination plan, communication plan, project management plan, and site 
performance plan should be finalized. 
• DSMB committee and charter finalized 
• Finalization of contracts and third-party agreements  
• EDC and data collection tools completed and in production. 
• Site training plan and its implementation at sites that have been activated 
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• Completion of regulatory approvals (FDA, IRB) 
• 25% of planned sites must be activated 
• One participant must be enrolled in the clinical trial before the end of year 1 
At the end of the UG3 phase, an evaluation meeting will take place between the 
PI and the NHLBI Program Official and if the milestones have been met satisfactorily, a 
UG3-UH3 transition discussion will be completed. This will allow the project to continue 
through the remaining years of funding. 
For the remaining years of funding, this section should specifically address the 
number of patients to be enrolled in the trial and the timing of other key events such as 
DSMB meetings, investigator study meetings and data analysis. In the final year of 
funding, the site timeline should include the process of data cleaning and analysis, timely 
closure of study sites, data sharing and dissemination time points, publication and 
presentation of study results and final close-out of the project with the NHLBI. 
At the end of this section, the study timeline should be presented in table format. 
This visual representation of the entire timeline noting key milestones is beneficial for 
reviewers to gauge the planned progress of the study in each year and identify any 
challenges that could stall project completion.  An example of this table is included in 






Chapter 5. Budget Development 
5.1. Budget components 
The NIH has two types of budget forms, and the correct form must be utilized 
based on the overall project budget. For projects that utilize greater than $250,000 in 
direct costs in any year of funding, an R&R Budget template is required. For projects less 
than $250,000 in direct costs per year of funding, a modular budget format is required. If 
the PI completed a staff consultation meeting and obtained an NHLBI acceptance letter, 
this would qualify for the R&R budget template, as the expected direct cost in any given 
year of funding is $500,000 or more. 
The total budget in direct costs should be within or precisely at the costs proposed 
to the NHLBI in the letter of intent and recorded on the acceptance letter. This letter will 
state the budget cap set for directs costs in year one of the project and the total budget cap 
for the project. The PI must ensure that neither of these budget caps is exceeded. For 
direct cost that is over the year one limit or total project budget, the NIH Program Officer 
should be consulted. This may require reinitiating the project application and staff 
consultation meeting and will add to the submission timeline. 
The budget should be built on an excel template and shared with the SPA 
administrator for review and for the addition of indirect costs (Appendix IX). Note that 
budget building is time-consuming, especially since the acceptance letter from the 
NHLBI will include the final approved budget cap for the study and there is no room to 
negotiate outside these approved numbers at the application stage. Budget negotiations 
may be permitted once the project is funded and the NHLBI accounting and agency 
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finance staff get involved in funding allocations. At this stage too, the room for 
negotiation remains marginal and may require strong justification with several rounds of 
discussion that could affect the project timelines. 
The budget requires the listing of line item costs under each category of expense, 
e.g., salaries, equipment, supplies, vendors, and sub-awards. A list of allowable costs and 
activities which can be billed to the grant can be found at: 
https://grants.nih.gov/grants/policy/nihgps/html5/section_7/7.9_allowability_of_costs_act
ivities.htm . 
Note that a budget justification page is also required as part of the application 
packet. Therefore, it is wise to incorporate details of each line item cost and associated 
rational on the excel spreadsheet to help create the justification document and for 
reference in the future.  
Salaries: The research team should gather the actual costs of salaries and fringe benefits 
for project personnel. For individuals at the applicant institution, human resources may be 
able to provide this information. Salaries should not be inflated for cost of living or 
promotions/raises. They should be stated at base salary plus fringe and benefits at the 
time of the application. The NHLBI recognizes that the cost of living raises will be 
requested if the project is funded.  For individuals with salary support requested through 
the grant, a time commitment for each year should be included to justify the costs. Time 
commitment can vary in each year of funding and salary support must equate to the 
person’s contribution.  
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The NIH places a salary cap in each fiscal year for all personnel included in the 
grant application. This cap is decided by the federal government and payment of salary 
for any individual being paid from the grant cannot exceed the Federal Executive Level II 
pay scale. The cap for fiscal year 2019 is set at $189,600. Individuals and collaborators 
budgeted on the grant who fall under the Executive Level II pay scale can obtain salary 
support to include base salary, fringe and benefits of up to $189,600 per year. If the 
individual’s salary is above this pay scale, the remainder of their salary must come from 
sources other than the grant. The PI must contact the institution SPA administrator for 
assistance with budgeting salary using the NIH cap for applicable individuals in each 
funding year of the grant. 
Using the definition of key personnel from section 4.4 of this manual, PI should 
determine which key person on the project will be budgeted to the grant and if the NIH 
salary cap is applicable to them. Salaries for key persons are listed on section A of the 
R&R budget form of the SF424 form. Note that it is not mandatory for key persons to be 
paid through the grant. For those key persons that do not require salary support from this 
grant, the PI should include a justification indicating the key person’s role and 
commitment to the project despite being paid through non-grant sources. 
For non-key persons such as research coordinators, pharmacist or administrative 
assistants who will be budgeted to the grant, obtain their base salary and fringe plus 
benefits and include these under section B of the R&R budget form. 
Consultants: For consultants, the total expense per year must be listed. It is advisable to 
collect a letter of support from the consultant outlining their experience to contribute to 
the project and clearly stating their time commitment and hourly billable rate. Note that a 
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strong justification for bringing consultants on board is required both by the NHLBI and 
almost always by the applicant institution. Consultants can be more expensive than 
salaried employees depending on their time commitment to the project, and therefore the 
justification to include them must be strong and clearly stated. Consultant fees are listed 
as a separate line item in section F of the R&R budget form.  
Sub-awards: Sub-awards must be detailed and itemized in terms of budgetary allocations 
and scope of work. Each sub-award must be listed separately with all the required 
information. Note that some academic institutions that provide services or collaborate on 
such large grants have their process of generating sub-award paperwork. It is advisable to 
initiate this process early, so all paperwork, approvals, and signatures are in place before 
the application deadline. Sub-award costs are listed under section F of the R&R budget 
form. 
Equipment: The NIH considers tangible property or equipment with a useful life of more 
than one year and cost of greater than $5000 per unit as equipment. Costs associated with 
purchasing project equipment must be itemized and listed through each year of funding in 
section C of the R&R budget form. The justification will explain any calculations, use of 
equipment via lease or purchase and duration of equipment use. Any maintenance 
contracts will also be included in this cost.  
Travel expenses: Travel associated with administering the grant can be budgeted to the 
project. The PI should expect to travel to the NHLBI at least twice in year one of funding 
and once every year after that. In the first year, the PI and additional key personnel or the 
project manager will travel to the NHLBI to review the project and participate in a kick- 
off meeting. Per the FOA, the project must achieve certain milestones by the end of year 
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one of funding when the NHLBI will evaluate progress and decide if the rest of the 
project should be funded. In subsequent years, meetings with the NHLBI staff can take 
place via conference calls, at national meetings or the NHLBI office. During the clinical 
trial, it is imperative to conduct study site visits at a few study locations. Travel costs for 
these visits must be calculated.  
The PI will also need to budget travel to national meetings to present study 
findings during the project and once the project analysis is completed. Travel costs and 
registration for national meetings must be included. To compute travel costs is advisable 
to use the published government per diem rates for the year of application for items such 
as airfare, mileage, hotel, food, and miscellaneous and incidental expenses. Using per 
diem rates make it easy to justify the cost of each trip and reassure the NHLBI that 
project dollars are not spent on expensive travel related to the study. Travel costs in each 
year are listed under section D of the R&R form. 
Supplies: Materials and supplies required for project execution are calculated to their 
best estimates. These are items that will be used to execute the project and can include 
items such as office supplies or lab reagents. For multi-site studies, for example, the 
applicant institution will provide regulatory binders to file study regulatory documents. 
Cost of each office supply item can be obtained from an online store and used to calculate 
the overall expenses related to this category. Computers can be listed under this category 
and billed to the grant if it will be used solely in the execution of the grant. The supply 
requirement and calculation of costs should be included in the budget justification 
document. The cost for supplies is listed under section F of the R&R form. 
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Site-specific expenses: Since this FOA applies to multi-site projects, reimbursement to 
the sites must be computed and included in the budget under section F of the R&R form. 
For clinical trials, sites can be reimbursed by per patient enrolled, a flat rate for screen 
fail subjects and other administrative costs such as report preparation and regulatory 
paperwork completion. These costs should be calculated by region (e.g., the US, Asia) 
and allocated to each year of the project budget. An explanation of how these costs were 
calculated is to be included on the budget justification page. 
IRB/Ethics Committee costs: The NIH has recently moved towards the requirement of 
multi-site projects needing to use a Central IRB for ethics oversight. This requirement 
extends to the chosen NHLBI announcement as well. In consultation with the applicant 
university, the PI should discuss which single IRB will provide ethics oversight of sites in 
the project. Note that if several countries are included on the project, the ethics committee 
requirements may vary based on regulations and the applicant university Human Subjects 
Protection Office may be able to guide in this regard. For sites within the US, several 
central IRB (CIRB) offer services and are prepared to work within the NIH expectations. 
The chosen CIRB can provide a letter of support outlining their services and 
accomplishments as well as their commitment to support the project if funded, along with 
a budget estimate. Including this letter in the submission indicates to the reviewers that 
preliminary work has been done and no additional time will be expended in getting 
project processes in place if the application is funded. The budget justification should 
include an explanation of IRB costs in each year of funding and the reviews the cost will 
cover such as the number of deviations, the number of expected events and the initial and 
annual submission at each site. 
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Site specific expenses and IRB costs can be grouped together and listed as other costs 
under section F of the R&R budget. 
Institutional Indirect costs: Once all direct costs are added, the PI should send the excel 
spreadsheet to the SPA administrator assigned to the project at the applicant university. 
This individual will review all line item costs for accuracy. If unallowable items are 
included, a discussion between the SPA administrator and PI should be arranged and 
corrections or substitutions made. Once finalized, the SPA will include the institutional 
indirect costs based on the Facilities and Administration (F&A) rate negotiated with the 
Department of Health and Human Services for federal grants. F&A costs typically cover 
institution SPA administrative costs to support the grant submission (pre-award) and 
activities in project execution (post-award) such as annual reporting, billing, compliance 
and oversight. Note that the indirect costs for the applicant institution are not included on 
the NHLBI acceptance letter. 
For sub-awards, the paperwork must include the sub-award institution F&A costs 
as well. To prevent duplicate billing of indirect costs, the applicant institution can charge 
its F&A costs only on the first $25,000 of the sub-award budget. This is to cover the 
applicant institutions efforts in administering the sub-award. 
5.2. Budget justification 
This is provided as a PDF attachment and uploaded on the budget sheet of the 
SF424 application. Each item with a cost listed on the project budget must be included on 
this document with an associated justification.  Salary for each individual should be 
explained along with their role and time commitment. Supply requests, travel and 
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consultant fees can be described and explained further in this section. Finally, the 
applicant institution’s indirect costs rate can be included in the justification so that 



















Chapter 6. Human subjects’ protection 
Clinical Trials involving human subjects must describe the plan to include the 
appropriate population through robust screening. The plan should also include steps to 
protect participants per the International Conference of Harmonization and Good Clinical 
Practice guidelines. 
The human subjects’ protection plan is written in four sections and uploaded as a 
PDF document. The section has no page limit and should be compiled as follows: 
A. Risks to Human Subjects 
B. Adequacy of Protection Against Risks 
C. Potential Benefits of the research to participants and others 
D. Importance of Knowledge to be gained. 
6.1. Risks to human subjects 
i. Human subjects’ involvement, characteristics, and design:  This section 
begins with a brief description of the overall study design.  Key-words such as 
randomized, double-blind, placebo-controlled should be included in the design 
description. The description sets the stage for the level of risks associated with 
the project, and this section must address how those risks will be identified, 
mitigated and controlled. This section should also describe the population 
under study. The clinical trial inclusion and exclusion criteria against which 
participants will be screened for study inclusion must be specified in detail. If 
there is more than one study intervention, these will be included here, and the 
method to assign each participant to a study intervention will be described 
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(e.g., randomized). Include the numbers of participants to be enrolled in each 
study intervention arm. Since the PAR-18-407 announcement involves a 
multi-site clinical trial, the role of participating sites in human subjects’ 
research should be described along with the contributions of participating 
collaborators. 
ii. Study procedures, materials, and potential risks: Details of all procedures to 
be conducted as part of the clinical trial will be included in this section. This 
includes visits to the study site by patients, procedures to be conducted at each 
visit (such as blood draws, questionnaires, obtaining medical history, and 
assessing adverse events) and data collection methods must be described. 
Include here, if protected health information (PHI) or identifiable information 
will be collected as part of the project and the process to ensure limited access 
and prevent a breach of confidentiality. The section should describe the 
known risks for each procedure and data collected. This could include risks of 
blood draws, discomfort in completing responses to questionnaires and risk to 
data safety from breach or loss of data. The section should be thorough and 
indicative that the PI and EC have evaluated risks associated with patient 
participation and has a plan to mitigate them appropriately. Typically risks in 
a clinical trial should be evaluated as physical, psychological, social, cultural, 
financial and legal risks. 
If alternative methods are available to help arrive at the same research 
outcome, those should be included with an explanation of why those methods 
are not being utilized or reserved as back-up strategies. 
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6.2. Adequacy of Protection against Risks 
i. Informed consent and assent: The informed consent process to be utilized on 
the clinical trial should be described. Information on the circumstances under 
which consent will be obtained should be included. The contents of the 
written informed consent and the process of documenting the consent should 
be included. If patients with an altered decision-making capacity or vulnerable 
patients are to be included, this should be described along with a plan to 
protect the rights and welfare of this population and all participants in the trial. 
If the use of a legally authorized representative or witness to the consent 
process will be allowed, circumstances for these should be described. If a 
waiver of some or all elements of consent will be obtained from the IRB, 
justification for the same should be noted. This FOA allows a sample 
informed consent form to be included as an appendix to the application. The 
research team should ensure the consent form submitted is written to include 
all essential elements as described by the Department of Health and Human 
Services, Office for Human Research Protections. 
ii. Protection against: The plans to protect, minimize and mitigate risks 
described above should be described in this section. This section should also 
include plans to protect data collected as part of the project, included PHI and 
identifiable information. Include who will have access to the data collected on 
the study and how this will be tracked. Where applicable, emergency 
intervention such as medical treatment to be provided or recommended should 
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be included. The process of emergency unblinding if applicable must also be 
included in this section. 
iii. Vulnerable subjects: The inclusion of vulnerable population in the clinical 
trial should be described here with justification for their inclusion. These 
would typically involve fetuses, pregnant women, children, prisoners, 
institutionalized individuals or others who could be considered vulnerable. 
6.3. Potential Benefits of the research to participants and others 
This section should describe the potential benefits of the research to participants 
and others and the knowledge to be gained from the project outcome. Benefits should not 
be overstated.  The section must include how the risks are reasonable compared to the 
potential benefits (risk-benefit ratio) of participation and the knowledge to be gained. The 
information included should not state the compensation offered to patients as a benefit of 
participation in the trial.  
6.4. Importance of knowledge to be gained 
The human subjects’ protection section should end with information on why the 
risks and processes undertaken are appropriate when compared to the knowledge to be 
gained from the project. If there are alternate research options available, their feasibility 








Chapter 7. Submission process 
 
7.1. Submission to the applicant university SPA 
The PI is notified of the applicant university’s internal submission deadline 
required to review the entire application before it is officially submitted to the NHLBI. 
All stakeholders must be aware of this deadline and make every effort to meet the 
timeline. Note that SPA administrators are assigned to work on several projects with the 
same submission deadline and project review can compete for their time and attention. 
The sooner the sections of the application are submitted for internal review; a more 
comprehensive and committed review can be completed by the assigned SPA 
administrator. These individuals are highly experienced with grant submissions and have 
a keen eye in identifying issues and discrepancies, and therefore, it is recommended that 
applicants utilize this facility judiciously. Applications that do not clear the internal 
institutional review process are most often not submitted officially to the NHLBI and can 
create tensions between the PI and institutional officials. 
It is recommended that once the budget and study justification is prepared, it is 
sent to the assigned university SPA administrator for review. This area of the application 
most often brings up surprises and needs several rounds of modifications before the 
budget is finalized. The budget justification is also revised to match any updates made to 
the budget numbers. 
As other documents related to the administrative sections of the application are 
completed, it is advisable to send them to the SPA administrator for review. Often the 
administrator will begin the official application in the system and upload the attachments 
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provided; to check for basic errors such as exceeded page limits and formatting issues. 
Errors from the system can help the PI revise the documents appropriately. Review of 
these documents by the SPA administrator also ensures that commitments made on 
project are realistic and within the achievable scope of the university. 
The university administrator may request the scientific sections to be submitted 
for internal review, a few days before the official submission deadline. SPA 
administrators routinely peruse these documents for formatting, grammatical errors and 
to confirm page limits are met. If they find contradictory information on the write-up, 
they may inquire with the PI. 
Once all changes are made, the SPA administrators will complete the official 
application online and attach all documents provided. They will share a copy of the draft 
application with the PI’s team. It is crucial that the PI, members of the EC and project 
manager review the draft application in detail to confirm all information is in order. At 
this point, the PI’s team should be reviewing all sections and information input on the 
application, including the fillable PDF sections completed by the administrator.  
Inconsistencies should be corrected, and the application reviewed multiple times until an 
error-free version is acceptable to all. This results in a final application version ready for 
official submission. 
7.2. Application submission through the grants portal. 
Once the final clean version is ready for submission and uploaded into 
www.grants.gov, the Authorized Official at the applicant university will sign the final 
application and complete the submission process through the federal grants submission 
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portal.  Note that the submitted application is time stamped by the system to include the 
date and time of portal submission in the applicant institution’s local time zone. For the 
PAR 18-407, the application must be submitted by 5 pm local time by the date noted on 
the application. An application submitted after this deadline is rejected by the system and 
will not proceed to NHLBI review. The Program Officer and staff at the NHLBI do not 
have the authority to override this requirement or grant exemptions to late submissions 
unless there is a technical issue with the federal grants submission portal. In such cases, a 
discussion would ensue with NHLBI officials and does not always result in obtaining 
permission to submit after the deadline.  To avoid delays and provide time to circumvent 
submission challenges, the NHLBI encourages applications to be uploaded and submitted 
a few days before the official deadline. 
Upon successful submission, the university official and PI receive an automated 
message noting the application was successfully submitted. The message includes the 
details of the submission. It also contains a note if warnings have been identified on the 
submission and instructions to access the application through eRA Commons to view the 
warnings. The instructions note that the institution has two business days retracted for 
corrections and a new application is uploaded, it overwrites the previous submission and 
allocates a new date/time-stamp of the application uploaded. If this time-stamp is after 
the official submission deadline, the application may get rejected. It is advisable in this 
scenario, to contact the NHLBI Program Officer and seek guidance on how to address 
and resubmit corrected applications. Changes to the application have to be routed through 




7.3. Scientific Review and feedback 
The applicant university or PI can be determined the status of the application 
through the eRA Commons account. When the status of the application is updated by the 
Scientific Review Officer (SRO), an e-mail notification is sent to the PI alerting him to a 
new status being available through eRA Commons.. The first status update is received a 
few weeks after the submission when the SRO has had a chance to review the submission 
for completeness. An update stating that the application has been received and will be 
assigned to a review committee is indicative that the submission is moving into the next 
stage of review. If there are missing documents, the e-mail would state the submission 
has been denied and include the reasons for the same. 
In subsequent weeks, an additional update is provided when the application is 
assigned to a scientific review committee and their meeting date has been finalized. The 
notification also states that the committee roster will be available approximately thirty 
days before the meeting date. The PI can log into eRA Commons and view this roster 
once available. Per NHLBI policy and as stated on the roster, the PI should not contact 
any of the committee members directly to discuss the application. Breach of this policy 
can result in the application being withdrawn from review and disqualified from future 
submissions. 
Between the official submission and up to 30 days before the Scientific Review 
Committee, any new information such as publications that could affect the design or 
outcome of the study or assist with scientific review can be submitted to the Scientific 
Review Officer to include in the review packet. Only relevant information should be 
submitted in these instances. 
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Following the Scientific Review Meeting and in approximately five business 
days, the raw score assigned to the application is uploaded into the eRA Commons 
account and is available to the PI and applicant university. Depending on the scores, the 
PI should reach out to the NHLBI Program Officer to discuss the review meeting and 
chances of funding. The application is scheduled to undergo Advisory Council review in 
eight weeks before the final decision for funding is announced. While there is not much 
the PI can do at this stage but wait for the final outcome, the Program Officer can share 
the application’s chance of success depending on the applications reviewed and general 
scoring assigned at the scientific review meeting. Approximately thirty days after the 
meeting, the summary statement noting reviewer comments is uploaded into the eRA 
Commons account. The PI and EC should access a copy of this statement and carefully 
review the feedback noted. If the comments appear to be indicative of an incomplete or 
inconsistent review, then the Program Officer should be contacted to express concerns 
and to determine the next steps. 
For projects that do not get funded, a resubmission may be possible. The Program 
Officer can provide guidance on the process to be followed. It should be noted here that a 
resubmission is assigned an alphabetic code indicating to the reviewers that the 
submission has been updated and resubmitted. It is strongly recommended that reviewer 
comments from the first round be addressed on the resubmission. If a recommendation 
made by a reviewer is not accepted, the resubmission application should justify the same. 
If changes are made in response to reviewer comments, the PI and EC should ensure the 
entire application continues to flow logically and the budget remains unaffected. 
Reviewers assigned to a resubmitted application may differ from the initial set of 
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reviewers. They perform reviews with a fresh set of eyes while also noting responses and 
changes made to previous critiques.    
The process to resubmit the application is as extensive as the original submission. 
Care should be taken to confirm that the FOA number or requirements have not changed. 
Efficient planning to submit a revised and stronger proposal should be done as there are 
limitations on the number of attempts for resubmission. Involving the Program Officer in 















Chapter 8. Conclusion. 
This manual is intended to be a useful tool in assisting and providing the PI and 
associate research team members with a roadmap to completing a strong and review 
worthy application in response to the PAR-18-407 announcement. The effectiveness of 
this manual is enhanced when the PI and the associated team members take steps to 
understand their project and the submission requirements. A successful submission must 
involve careful planning, the interaction between team members and the need to be 
organized and systematic throughout the application process.  
Following this manual and referencing it routinely during the application 
development period will allow the PI to strategize the inclusion and placement of content, 
assign the development of application sections to team members, administrators within 
the sponsored program office, and collaborators.  
Please refer to the appendices for sample templates of documents used in the 
PAR-18-407 submission as noted in the respective sections of this manual. 
The grant writing and submission process is challenging, arduous, and stressful. 
An unwavering passion for research with a commitment to succeed must remain at the 
forefront of the application process. The author of the manual wishes all applicants 






Appendix 1. NIH checklist 
*checklist does not replace the solicitation. Please review program specific solicitation 
for compliance and completeness.  
DUE DATE AND AWARD INFORMATION 
Internal applicant 
university deadline 
XXX days prior to NHLBI submission deadline 
Internal submission due date: 
 
The following will be the minimal information required to 
meet the Internal SPA deadline  
1.Working Title of proposal 
2.Key Personnel, their roles and effort 
3.Budget and Budget Justification 
4.Information on whether animal and human subjects will 
be part of this research  
5. Award length (how many years the grant will be 
awarded for)  
6. Any subcontracts? With who? 
7.Any keywords associated with your grant proposal 
 
Award notification At least 6 months after grant submission due date 
LOI due date 30 days prior to application due date 
Targeted application due 
date 
5:00PM local time on DD/MMM/YYYY  
Scientific Committee review in MMM/YYYY 
Advisory council review MMM/YYYY 
Earliest start date of funding MMM/YYYY 
For application requesting $500,000 or more in direct 






PDF only; no headers or footers 
Font 
type/size 
Arial, Georgia, Helvetica, Palatino Linotype 
11 or larger (smaller txt in figures, graphs charts is acceptable as long as 
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they are legible when page view if 100%) 
Black font color 
Line 
spacing 
No more than 6 lines of type within a vertical space of 1 inch  
No more than 15 characters per linear inch (including characters and 
spaces) 
Page size 8.5 x 11 
Margins 0.5” all sides 
Guidelines 
Announcement: 
CCC application 18-407 
https://grants.nih.gov/grants/guide/pa-files/PAR-18-407.html  
DCC application 18-410 
https://grants.nih.gov/grants/guide/pa-files/PAR-18-410.html  
  
SF 424 R&R application guide for research: 
https://grants.nih.gov/grants/how-to-apply-application-guide/forms-
e/research-forms-e.pdf   
  
 
PROPOSAL DOCUMENTS  
 Assigned to Documents:  
Status  
1.   




• Descriptive title 
• Name/address/telephone number of proposed PI 
• Names of other key personnel 
• Participating institutions 
• Number and title of FOA 
Send letter to: 
Director, Office of Scientific Review  




National Institutes of Health 
6701 Rockledge Drive, Room 7214 
Bethesda, MD 20892-7924 (Express Mail Zip:  20817) 
Telephone: 301-435-0270 
Email: NHLBIChiefReviewBranch@nhlbi.nih.gov 
1   Cover Letter Attachment: PDF attachment/no page limit 
 
  
The following collaborative information is required in 
the Cover Letter as one PDF file:  
• The PD/PI(s) name(s),  
• Title of FOA 
• The Title (including the tag, e.g., “1/3”)  
• The Applicant Institution. Each site should 
submit an identical listing. 
• Statement that agency approval for >$500,000 is 
included 
• Statement if proposed study will generate large-
scale human or non-human genomic data 
Note: If the direct costs of the combined CCC and 
DCC budgets equal or exceed $500,000 in any given 
year, a copy of the NHLBI approval letter must be 
attached. 
 
2.  Descriptive Title of Applicant's Project: PDF attachment/ Limit to 200 characters  
 
  
To allow NHLBI to identify a group of applications as a 
related set of collaborative applications, the titles for 
each application in the set must have the following 
format:  
• A “1/N” indicator + Identical Title (e.g., “1/3”, 
where the 1/3 means this is site 1 of 3 sites in the 
set. The other sites will be labeled 2/3, etc.) 
• Titles may not exceed 200 characters in length, 
including the tag, e.g., 1/3, at the beginning of 
the title. 
 
3  Project Summary/Abstract - PDF attachment/No 
longer than 30 lines of text  
 
  
• State the application’s broad, long-term 
objectives and specific aims, referring to the 
health relatedness of the project/ relevance of 
mission of agency. 






4  Project Narrative – PDF attachment/No more than three sentences 
 
  • Describe the relevance of this research to public 
health 
 
5  Bibliography & References Cited – PDF attachment/ 
No page limit 
 
  
• Each reference must include the names of all 
authors (in the same sequence in which they 
appear in the publication), the article and journal 
title, book title, volume number, page numbers, 
and year of publication. 
• When citing articles that fall under the Public 
Access Policy, were authored or co-authored 
by the applicant and arose from NIH support, 
provide the NIH Manuscript Submission 
reference number (e.g., NIHMS97531) or the 
PubMed Central (PMC) reference number (e.g., 
PMCID234567) for each article. If the PMCID is 
not yet available because the Journal submits 
articles directly to PMC on behalf of their 
authors, indicate “PMC Journal – In Process.” 
 
For interim research products follow: 
https://grants.nih.gov/grants/interim_product_faqs.htm  
 




• Describe how the scientific environment in 
which research will be done contributes to 
probability of success (institutional support, 
physical resources, intellectual rapport). 
• Describe how the proposed study will benefit 
from the unique features of the scientific 
environment or from unique subject populations. 
• Describe resources available at each site for 
multiple performance sites ( obtain information 
from site survey) 
 
7  Equipment – PDF attachment/No page limit  
  
• List major items of equipment already available 
for this project and, if appropriate identify 
location and pertinent capabilities. 
 





• Use NIH biosketch format - 
https://grants.nih.gov/grants/forms/biosketch.ht
m  
• Must Include eRA Commons User Name. 
• Applications should include only its own 
personnel and respective biographical sketches. 
• List Key personnel for CCC ONLY. 
• All Key Personnel who are major contributors to 
the study must provide an NIH Biosketch 
whether or not they are budgeted.  
• The PI (or multiple PIs) for the CCC cannot be 
Key Personnel on the DCC application. 
• The PI(s) of the clinical trial must be 
experienced in the conduct of multi-center 
clinical trial coordination and management, 
including success in meeting milestones and 
timelines, and have expertise in the content area 
of the proposed clinical trial. The experience of 
each PI and all Key Personnel must be carefully 
documented and roles and responsibilities must 
be well defined. In addition, the responsibilities 
and authority of each PI must be specified. 
 
9  Specific Aims – PDF attachment/Limited to one page   
  
• State concisely the goals of the research and 
summarize the expected outcome(s), including 
the impact that the results of the proposed 
research will exert on the research field(s) 
involved. 
• List succinctly, the specific objectives of the 
proposed research (to test the stated hypothesis, 
solve a specific problem, challenge an existing 
paradigm or clinical practice, address a critical 
barrier to progress in a field etc) 
 
 





• The Research Strategy must present an overview 
of the state of the science, status and relevance 
of the trial, a detailed discussion of the specific 
protocol, and the approach to data collection. It 
should include a brief description of study 
research objectives.  
Significance (per FOA) 
• Explain the importance of the proposed clinical 
trial and importance of the question must be 
clearly stated. 
• Explain how the proposed project will test the 
proposed hypotheses and why there is clinical 
equipoise. 
• Application should make clearly the need and 
timeliness of the study with emphasis on how the 
results will address an evidence gap and advance 
knowledge of theory and practice areas. Include 
a description of how the results will impact 
clinical care to improve health 
• Include a discussion on the costs and benefits of 
the study elated to trial significance 
Innovation 
• Explain how the application challenges and 
seeks to shift current research or clinical practice 
paradigms. 
Approach 
• This section should include a description of the 
supporting data, the experimental approach  
a. Experimental Approach  
Describe critical features of the trial that are not 
already described in the PHS Human subjects 
clinical trials information to include the 
following: 
o A detailed description and rationale for 
research hypothesis and rational for 
specific design chosen (pragmatic, 
randomized, unblinded etc).  
o A detailed description of the study 
population and why it is the most 
appropriate group to answer the question. 
o Detailed description and justification of 
all assessments such as clinical, lab, pt 
centered, behavioral, physiological and 
other outcomes addressing primary and 
secondary research questions. Use of pt 
reported outcomes as well as non-
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traditional data collection methods 
(telephone, mobile, web-based systems 
etc)  
o Implementation and monitoring of GCP 
o Discussion of potential challenges in 
implementing the research protocol and 
how they will be addressed. Contingency 
plans if the effect size or event rate in 
underestimated. 
o Participant f/u procedures 
b. Supporting Data: 
o Describe the formative clinical studies 
(including any pilot studies) that are the 
basis for the proposed clinical trial. 
Include other research as appropriate to 
demonstrate that the approach chosen is 
justified.  
o If the clinical trial is Phase III, include 
relevant data used to determine that the 
proposed trial includes adequate numbers 
of subgroups of participants to allow for 
separate and adequately powered 
analyses. 
o For Phase III trials, include relevant data 
used to propose the adequate number of 
subgroups for a separate and adequately 
powered analysis. 
11  Letters of support: PDF attachment/No page limit  
  
• Letters of support from clinicians or clinical 
department chairs whose support are necessary 
to the successful conduct of the trial should be 
provided. 
• If parts of the costs of the trial are to be provided 
by sources other than NHLBI, provide Letter(s) 




12   
  
 
  • Data sharing Plan: Brief 1 paragraph description 




sharing is not possible. 
• Include a Data Sharing Plan with schedule for 
data sharing, format of final data set, 
documentation to be provided, analytical tools to 
be provided, if any, need for data sharing 
agreement, mode of data sharing. 
• Data sharing tips: 
https://grants.nih.gov/grants/policy/data_sharing/
data_sharing_workbook.pdf  
13  Appendix   
  • FOA PAR-18-407  allows only the consent form 
as an appendix 
 
14  Inclusion of women and minorities and children: 
PDF attachment/ No Page limit 
 
  
• This information must be the same as on the 
DCC application submitted under FOA PAR-18-
410. 
• Describe the planned distribution of subjects by 
sex/gender, race, and ethnicity.  
• Describe the rationale for selection of 
sex/gender, racial, and ethnic group members in 
terms of the scientific objectives and proposed 
study design. The description may include, but is 
not limited to, information on the population 
characteristics of the disease or condition under 
study.  
• Describe proposed outreach programs for 
recruiting sex/gender, racial, and ethnic group 
members.  
• Inclusion and Excluded Groups: Provide a 
reason for limiting inclusion of any group by 
sex/gender, race, and/or ethnicity. In general, the 
cost of recruiting certain groups and/or 
geographic location alone are not acceptable 
reasons for exclusion of groups.  
• Existing datasets are resources: if existing 
datasets, resources or samples from other studies 
are used, address their inclusion 
For NIH phase III clinical trials: 
• It is mandatory to address plans for how 
sex/gender, race and ethnicity will be taken into 






• Inclusive eligibility criteria: cost of recruiting 
certain groups or geographic location alone are 
not acceptable to exclude a group. 
• Allocation of study participants of both sexes 
and from different racial and ethnic backgrounds 
to the study arms by an unbiased process such as 
randomization. 
• Unbiased evaluation of the outcomes of study 
participants. 
• Use of unbiased statistical analysis and proper 
methods of inference to estimate and compare 
intervention effects by sex/gender, race and or 
ethnicity, particularly if prior evidence strongly 
suggests that differences exist. 
• Plans to tests for differences if effect among 
sex/gender, racial and ethnic groups through 
discussion of one of the following: 
a. Address whether analysis will be done to detect 
significant differences in intervention effect 
along sex, race and ethnicity when prior studies 
strongly suggest there are significant differences 
amongst subgroups   OR 
b. Plans to include and analyze sex/gender, racial, 
and/or ethnic subgroups when prior studies 
strongly support no significant differences in 
intervention effect between subgroups. 
(Representation of sex/gender, racial, and ethnic 
groups is not required as subject selection 
criteria, but inclusion is encouraged.), or  
c. Plans to conduct valid analyses of the 
intervention effect in sex/gender, racial, and/or 
ethnic subgroups (without requiring high 
statistical power for each subgroup) when the 
prior studies neither support nor negate 
significant differences in intervention effect 
among subgroups.  
15  Recruitment and Retention Plan: PDF 
attachment/No page limit 
 
  
• Expertise of individuals responsible for 
screening, approaching and consenting potential 
pts. 
• Engagement of pt advocacy groups. 
• Process for identification and screening of study 
participants. 
• Primary and back-up recruitment strategies (use 




• Implementation of consent processes. 
• Participant adherence and retention strategies. 
• Safeguards for vulnerable population if 
applicable. 
• Possible competing trials for participants. 
• Engagement of communities that will play a 
critical role in recruitment and retention. 
• Recruitment of groups for cluster-randomized 
trials. Provide a table of recruiting sites with site 
PI, showing enrollment goals and number of 
potential participants available for each site. 
16.  Study Timeline: PDF attachment/No page limit  
  
Provide a both description and table/graph of the overall 
study timeline and key milestones 
• Overall study timeline: include estimated time of 
study duration (in months) including when study 
opens to enrollment and final transfer of data to 
DCC will occur. Describe key milestones that 
need to be met throughout the trial (UG3 and 
UH3 phases), timetable of when these 
milestones will be met. 
• Aim of the CCC milestone plan is to describe 
those that need to be met by the CCC in 
coordination with activities of the DCC. 
• Key milestones: include relevant, measurable, 
results-focused and time-bound milestones for 
overall recruitment, enrollment and retention 
goals. Address milestones accrual goals for 
women, minorities and children and any other 
requirements for completion of approved 
research. 
• Include milestones for UG3 phase that should be 
met to successfully transition to the UH3 phase. 
Overall enrollment and site participation 
expected by the end of the UG3 phase will be 
agreed upon by the PI and NHLBI prior to 
award. Generally- one participant must be 
enrolled and 25% of sites activated at the end of 
UG3 phase. Describe milestones in UH3 phase 
to address specific aims and ensure successful 
completion of trial and dissemination of results. 
• Important milestones for CCC include: 
• Complete finalized protocol 
• Finalized ICF 




• Training of sites 
• Final management/communication 
plan 
• Final data and safety monitoring plan 
• Site performance plan 
• Data completeness and quality 
monitoring reporting plan 
• Completion of regulatory approvals 
• 25% of sites activated 
• Enrollment of first subject in UG3 
phase 
• UG3-UH3 transition meeting 
• Enrollment of 25%, 50%, 75% and 
100% of projected recruitment, 
including women and minorities 
• Assessment of sites protocol 
implementation performance 
• Collection of data related to primary 
and secondary endpoints and database 
lock 
• Submission of primary manuscript to 
peer-reviewed scientific journals and 
dissemination of results 
• Submission of study results to 
clinicaltrials.gov within 12 months of 
primary completion date 
 
NHLBI will conduct at least 2 admin reviews to 
determine progress: one at end of UG3 phase and the 
second within 2 years of the UH3 phase. The first may 
result in the revision of the milestones during the 
UG3/UH3 transition phase. 




Section A: Risks to human subjects 
A(i) Human subject’s involvement, characteristics and 
design: 
Briefly describe the overall study design.  
Describe the subject population(s) to be included in the 
study; the procedures for assignment to a study group, if 
relevant; and the anticipated numbers of subjects for 
each study group.  
List any collaborating sites where human subjects 




those sites and collaborating investigators in performing 
the proposed research  
A(ii) Study Procedures, Materials, and Potential Risks  
Describe all planned research procedures (interventions 
and interactions) involving study subjects; how research 
material, including biospecimens, data, and/or records, 
will be obtained; and whether any private identifiable 
information will be collected in the proposed research 
project.  
For studies that will include the use of previously 
collected biospecimens, data or records, describe the 
source of these materials, whether these can be linked 
with living individuals, and who will be able to link the 
materials.  
Describe all the potential risks to subjects associated 
with each study intervention, procedure or interaction, 
including physical, psychological, social, cultural, 
financial, and legal risks; risks to privacy and/or 
confidentiality; or other risks. Discuss the risk level and 
the likely impact to subjects.  
Where appropriate, describe alternative treatments and 
procedures, including their risks and potential benefits. 
When alternative treatments or procedures are possible, 
make the rationale for the proposed approach clear. 
 
Section B Adequacy of Protection Against Risks 
B(i). Informed Consent and Assent  
Describe the process for obtaining informed consent. 
Include a description of the circumstances under which 
consent will be sought and obtained, who will seek it, 
the nature of the information to be provided to 
prospective subjects, and the method of documenting 
consent. When appropriate, describe how potential adult 
subjects’ capacity to consent will be determined and the 
plans for obtaining consent from a legally authorized 
representative for adult subjects not able to consent.  
If a waiver of some or all of the elements of informed 
consent will be sought, provide justification for the 
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waiver. Do not submit informed consent document(s) 
with your application unless you are requested to do so 
B(ii) Protections Against Risk  
Describe planned strategies for protecting against or 
minimizing all potential risks identified, including 
strategies to manage and protect the privacy of 
participants and confidentiality of research data.  
Where appropriate, discuss plans for ensuring necessary 
medical or professional intervention in the event of 
adverse effects on participants.  
Describe plans for handling incidental findings, such as 
those from research imaging, screening tests, or 
paternity tests.  
 
B(iii). Vulnerable Subjects, if relevant to your study 
Explain the rationale for the involvement of special 
vulnerable populations, such as fetuses, neonates, 
pregnant women, children, prisoners, institutionalized 
individuals, or others who may be considered vulnerable 
populations.  
 
Section C: Potential Benefits of the proposed 
Research to Research Participants and others 
Discuss the potential benefits of the research to research 
participants and others.  
Discuss why the risks to subjects are reasonable in 
relation to the anticipated benefits to research 
participants and others.  
Note: Financial compensation of subjects should not be 
presented as a benefit of participation in research. 
 
Section D: Importance of the Knowledge to be 
Gained  
Discuss the importance of the knowledge to be gained 
as a result of the proposed research.  
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Discuss why the risks to subjects are reasonable in 
relation to the importance of the knowledge that 
reasonably may be expected to result. 
 
18  Single IRB Plan: PDF attachment/no page limit  
  
• Describe the single IRB Plan (should be same as 
DCC application). 
• Describe how you will comply with the NIH 
Policy on the Use of sIRB for Multi-Site 
Research.  
• Provide the name of the IRB that will serve as 
the sIRB of record.  
• Indicate that all identified participating sites 
have agreed to rely on the proposed sIRB and 
that any sites added after award will rely on the 
sIRB.  
• Briefly describe how communication between 
sites and the sIRB will be handled.  
• Indicate that all participating sites will, prior to 
initiating the study, sign an 
authorization/reliance agreement that will clarify 
the roles and responsibilities of the sIRB and 
participating sites.  
• Indicate which institution or entity will maintain 
records of the authorization/reliance agreements 
and of the communication plan.  
Note: Do not include the authorization/reliance 
agreement(s) or the communication plan(s) documents 
in your application.  
For Studies with Legal, Regulatory, or Policy-based 
Claims for Exception as described by the sIRB 
Policy: Indicate that review by a sIRB will not be 
possible for all or some sites (specify which sites) 
because local IRB review is required by an existing 
federal/state/tribal law or policy. Include a specific 
citation to the relevant law, policy, or regulation. 
For sites requesting an exception based on 
compelling justification: Indicate which site(s) is 
requesting an exception to the use of the sIRB and 
provide compelling justification based on ethical or 
human subjects’ protection issues or other well-justified 




exception following an assessment of the need. Note: If 
you intend to request an exception to the sIRB policy 
based on compelling justification, do not account for 
this exception in your proposed budget. The proposed 
budget must reflect any necessary sIRB costs without an 
exception (i.e., applicants should not assume that an 
exception will be granted when considering what sIRB 
costs to include in the budget). 
19  Data and safety monitoring plan: PDF 
attachment/no page limit 
 
  
This section should be the same as provided in the DCC 
application. 
• Specify criteria for adverse event reporting, 
intervention discontinuation and stopping 
guidelines 
• For any proposed clinical trial, NIH requires a 
data and safety monitoring plan (DSMP) that is 
commensurate with the risks of the trial, its size, 
and its complexity. Provide a description of the 
DSMP, including:  
• The overall framework for safety monitoring and 
what information will be monitored.  
• The frequency of monitoring, including any 
plans for interim analysis and stopping rules (if 
applicable).  
• The process by which Adverse Events (AEs), 
including Serious Adverse Events (SAEs) such 
as deaths, hospitalizations, and life threatening 
events and Unanticipated Problems (UPs), will 
be managed and reported, as required, to the 
IRB, the person or group responsible for 
monitoring, the awarding IC, the NIH Office of 
Biotechnology Activities, and the Food and 
Drug Administration.  
• The individual(s) or group that will be 
responsible for trial monitoring and advising the 
appointing entity. Because the DSMP will 
depend on potential risks, complexity, and the 
nature of the trial, a number of options for 
monitoring are possible. These include, but are 
not limited to, monitoring by a:  
• PD/PI: While the PD/PI must ensure that the trial 
is conducted according to the approved protocol, 




it may be acceptable for the PD/PI to also be 
responsible for carrying out the DSMP. o 
• Independent safety monitor/designated medical 
monitor: a physician or other expert who is 
independent of the study. 
• Independent Monitoring Committee or Safety 
Monitoring Committee: a small group of 
independent experts. 
• Data and Safety Monitoring Board (DSMB): a 
formal independent board of experts including 
investigators and biostatisticians. NIH requires 
the establishment of DSMBs for multi-site 
clinical trials involving interventions that entail 
potential risk to the participants, and generally, 
for all Phase III clinical trials, although Phase I 
and Phase II clinical trials may also need 
DSMBs. If a DSMB is used, please describe the 
general composition of the Board without 
naming specific individuals. 
 
20  
Structure of the project team: PDF attachment/no 
page limit   
      
 
  
• Include role of executive committee and steering 
committee and any internal or external advisory 
committee 
• Describe the oversight, responsibilities and 
coordination of sites or cores proposed 
• Describe role of any sub-investigators or 
providers, services, personnel or facilities.  
• Describe how these functions will integrate with 
the organizational framework with the DCC. 
• How DCC and CCC will coordinate leadership 
of clinical trial implementation and 
communications  
• Coordination with the separate components 
including NHLBI 
• Key channels used to reach and inform each 
stakeholder group and receive feedback. 











• Include a brief statement indicating that the CCC 
has worked closely with the DCC to ensure the 
number of expected subjects, expected effect 
size, power and statistical methods (for each 
outcome measure) have been adequately 
addressed. 
• State that the statistical design and power 
attachment is being submitted entirely as part of 
the collaborating DCC application. 
• Specify the number of subjects you expect to 
enroll, the expected effect size, the power, and 
the statistical methods you will use with respect 
to each outcome measures. 
• You will need to show that your methods for 
sample size and data analysis are appropriate 
given your plans for assignment of participants 
and delivery of interventions. For trials that 
randomize groups or deliver interventions to 
groups, special methods are required; additional 




22  Dissemination Plan :PDF attachment/ no attachment  
  
This must be the same as described in the DCC 
application  
Explain briefly your plan for the dissemination of NIH-
funded clinical trial information and address how the 
expectations of the policy will be met. The plan must 
contain sufficient information to assure the following:  
• The applicant will ensure that clinical trial(s) 
under the award are registered and results 
information is submitted to ClinicalTrials.gov as 
outlined in the policy and per the specific 
timelines stated in the policy;  
• Informed consent documents for the clinical 
trial(s) will include a specific statement relating 
to posting of clinical trial information at 
ClinicalTrials.gov 
• The recipient institution has an internal policy in 
place to ensure that clinical trials registration and 






23  Budgets – Modular or non-modular  
  Non-Modular/detailed – requesting more than 
$250,000 per year in direct costs. 
 
  
• Proposals that seek more than $500,000 in direct 
costs per year must be granted special permission 
from NIH. 
• The current NIH salary cap is $189,600 
• Each application in the cluster must include only 
its own budget, including any associated sub-
awards 
• Separate itemized budgets for each subcontract 
• Budget justification to include details needs for 
each year 
• Cores must be subcontracts to either CCC or 
DCC 
• Include budget support for personnel to travel to 
DC for a yearly in person Steering Committee or 
investigator meeting/ NHLBI staff meetings 
• Include budget support for publication and 
dissemination of results. 
• DO NOT include budget for DSMB in CCC. 
This should be included in the DCC budget only. 
 
 
25  Budget Justifications: PDF attachment/ no page limit  
  
Personnel Justification (applicable only to modular 
budgets) 
• List all personnel including names, number of 
person months (not % effort) devoted to the 
project (indicate academic, calendar, and/or 
summer) and roles on the project. Do not provide 
individual salary information. 




• A detailed cost breakdown by cost category. 
• All costs requested and all changes in the budget 










































































Appendix III. Cover Letter template 
On applicant institutional letter head 
 
PI’s name, designation and contact information 
 
NHLBI Division Director’s name 
Director, Division of Cardiovascular Sciences (DCVS) 




Dear (NHLBI Division Director) 
I am including our submission titled “1/N Project Title” for consideration under the 
FOA: (PAR18-407), “Clinical Coordinating Center for Multi-Site Investigator-Initiated 
Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)”. The applicant 
institution is (Name of applicant institution). The budget for year one in direct costs is $ 
(year 1 direct costs approved by NHLBI) and for the overall study (X years) is $ (total 
direct costs of project approved by NHLBI) 
 
This submission is part of a cluster that contains XXX applications and they are: 
1. Project 1/2 Clinical Coordinating Center (CCC) application: 
    Principal Investigator:  Include PI name, designation and university information 
2. Project 2/2 Data Coordinating Center (DCC) application: 
    Principal Investigator:  Include PI name, designation and university information 
No human or non-human genomic data will be generated in the proposed trial. There are 
no sub-award budgets that are not active in all periods. 
Since the requested budget of the proposed grant in each period exceeds $500,000 in 
direct costs a copy of the NHLBI acceptance letter to review this proposal is included.  
I thank you for considering our request for support. 
  
Sincerely, 
PI name and signature 
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Appendix IV. NIH Biographical sketch for Key personnel 
OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020) 
BIOGRAPHICAL SKETCH 
Provide the following information for the Senior/key personnel and other significant 
contributors. Follow this format for each person.  DO NOT EXCEED FIVE PAGES. 
NAME: Johns Doe, MD 
eRA COMMONS USER NAME (credential, e.g., agency login): JDOE 
POSITION TITLE: Director, Center for Coronary Interventions, and Professor of 
Medicine XXX University 
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional 
education, such as nursing, include postdoctoral training and residency training if 



















Residency MM/YYYY Internal Medicine 
University XXX, 
Dallas, Tx 




Fellowship MM/YYYY Interventional 
Cardiology 
    
    
 
A. Personal Statement 
 
On the proposed application “Project Title”, I will function as the project PI. My 
experience includes serving as a Principal Investigator on several multi-site clinical trials 
since 2008 specializing in the field of coronary intervention. I recently completed a multi-
site randomized, controlled, double-blinded clinical trial in (project area) funded by the 
NIH through the R01 mechanism to study (include project objective).  I have also served 
as the PI of data coordinating centers that create, manage, and control data quality in the 
area of (project area) over the last XXX years. As a PI of these studies, I have overseen 
data management and development of case report forms, patient safety, risk management, 
project management and statistical methods.  I have served as a member of Data and 
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Safety Monitoring Boards (DSMB), both on industry sponsored and NIH trials. I have 
also been a member of study Executive Committees. I have over 18 years’ experience in 
coordinating, building and managing patient registry databases. The XXX (project title) 
trial in keeping with the philosophy to promote research and equipped with the 
experience of the study leadership will provide evidence-based knowledge to the medical 
community regarding a largely unanswered question on XXX (project objective) 
 
B.  Positions and Honors 
 
List major positions and honors in this section by year. 
 
Other Experience and Professional Memberships 
List important professional memberships here 
 
C. Contributions to Science 
 
List 5 of the most current contributions to science here. For each contribution, list up to 4 
related publications. Contribution can include trials conducted and their outcomes, 
publications such as books etc. 
 
Complete List of Published Work:   Insert link to complete bibliography of publications 
obtained from NIH MyBibliography page 
 
D. Additional Information: Research Support and/or Scholastic Performance  
 
List ongoing research here in the format noted below. 
 
Sponsor name   Role in Project    Dates of 
project  
Title of project 
 
Sponsor name   Role in Project    Dates of 
project  
Title of project 
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Clinical Coordinating Center 
(CCC) 
 







Study executive committee (EC): List names of personnel 
  
CCC: Name of Institution 
 





















Site name and address 
 
 
Site PI Name:  
Site PI Specialty:  
Site PI e-mail address 
 
 
Site PI phone number 
 
 









Name and address of hospital where study 
will be conducted 
 
Are you interested in participating in XXX 
Trial? 
o Yes        
o No 
On an average, how many patients per 
month with ( insert main inclusion criteria 
here) at your hospital 
 
 
_______________ patients per month 
Of the numbers of patients per month noted 
above, how many patients would be 
eligible for this trial based on the 





IRB/Ethics Committee information 




If yes, select all CIRB reviews acceptable o Copernicus IRB 
o Western IRB 






Does your local IRB/site have a reliance 
agreement with a CIRB 
o Yes: Specify___________________ 
o No 
Does you site need approval form othet 







Facilities and Resources 




Do you have adequate space with limited 
access to control research materials (lab 
kits, study charts) 
o Yes 
o No 
Does your site have research coordinators 
that can be assigned to this trial? 
o Yes 
o No 
Does you site have access to a compute to 
randomize patients and enter study data? 
o Yes 
o No 




Does your site have a dedicated research 




If no, please describe where study 























Appendix VII. Letter of Support from Participating Site 
 
Please insert organization’s letterhead) 
Enter Project PI name and institution 
Date 
Re: Enter project title 
Dear Dr. XXXX, 
I am pleased to state my interest in participating as the Site Principal Investigator in the 
XXX Trial (insert project title), involving …state study objective. 
Our hospital is commonly faced with this clinical question involving the care of 
cardiovascular patients with this condition and as the Principal Investigator at 
_______________, (insert site name) I would like to participate in this first randomized 
clinical that would benefit patients and providers alike. We have the necessary patient 
population to approach and can enroll____ patients per month into this study. We are 
willing to collaborate with providers across specialties to build a referral base.   
Sincerely, 














Appendix VIII. Study timelines template 
 
 
UG3 Phase  
Study process Timeline (MMM/YYYY) 
Study protocol, ICF, case report forms. 
Form study management groups. Finalize 
SOP and process documents for each group 
Jan-Mar YYYY 
Project personnel and site training plan and 
manual 
Mar-Apr YYYY 
Primary and back-up site selections Feb-Apr YYYY 
 
EDC set-up Apr-May YYYY 
 
Site Contracting Apr- Jun YYYY 
 
Central IRB contracting and submissions. 
Approval of first 5 sites. 
Apr-Jun YYY 
DSMB, CEC, other committees 
(formation/charter), regional hubs 
Jun-Jul YYYY 
Site training/initiation (25% of total 
planned) 
Jul-Oct YYYY 
First patient enrolled Nov-Dec YYY 
 
 




Study process Timeline (MMM/YYYY) 
Activation of remaining sites Jan –Mar YYYY (year 2) 
Enrollment of up to 200 patients Jan-Dec YYYY (year 2) 
Enrollment of patients 201-500 Jan-Dec YYYY (year 3) 
Enrollment of patients 501-800 
(Interim analysis at Pt #658) 
Jan-Dec YYYY (year 4) 
Enrollment of patients 801-1000 Jan-Sep YYYY (year 5) 
Last Patient Last visit Oct YYYY (Year 5) 
Data clean up, and database lock Jun-Dec YYYY (Year 5) 
Statistical analysis Nov-Dec YYYY (Year 5) 
Publication/Presentation and Data 
submission to NHLBI central repository 






Appendix IX. Budget template 
 
Budget template for year 1 of funding is included here. This template can be duplicated to 

































Appendix 2. Biography 
 
Preeti P Kamath is currently a Clinical Team Manager with a large CRO and oversees 
clinical trials in North America. Prior to her current role, she was the Clinical Research 
Manager at a premier medical university and academic center in Dallas, Texas. She 
served as the Project Manager on several clinical trials funded by pharmaceutical/device 
companies and Federal agencies such as the Veterans Health Administration and National 
Institutes of Health.  She has also held the role of research coordinator and IRB 
Administrator in her career spanning 12 years in the field of research. She is a dentist by 
training and received her Bachelor’s in Dental Surgery degree from Bangalore, India and 
Master’s in Healthcare Administration from University of Texas, Arlington prior to 
completing her Master of Science in Research Administration at Johns Hopkins 
University. 
 
  
